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ABSTRACT
Small Cell Lung Cancer (SCLC) is a devastating disease characterized by a very low two-year
survival rate and almost universal acquisition of chemoresistance. Nearly all patients have
tumors driven by functional inactivation of the tumor suppressors Rb and p53, but despite the
uniform origins of this tumor, not all patients are genetically or phenotypically identical. SCLC
can be subtyped into four unique molecular subtypes, determined by the expression of ASCL1,
NEUROD1, POU2F3, or YAP1. These subtypes are plastic, and subtype switching after
chemotherapy has been documented. Without the understanding of how tumor heterogeneity
arises, we cannot solve the challenge of chemoresistance in SCLC. In recent years, a powerful
new tool in studying tumor heterogeneity has emerged. Genetic barcoding allows for the
identification and tracking of individual tumor populations by inserting a small genetic sequence
(“barcode”) into the genome of tumor cells. As the cells divide, the barcode is passed on and a
high-resolution lineage map is constructed. Here, genetic barcoding is used for the first time in
SCLC, combined with single-cell RNA sequencing in a genetically engineered mouse model and
a xenograft model of SCLC.
In the mouse model of SCLC, tumors were sequenced at early, middle, and late stages of tumor
development, as well as chemoresistant tumors. While no barcodes were detected by scRNA-seq,
valuable information about the process of tumor development in SCLC is observed. I identify
two cellular populations (“early” and “late”) that arise during tumor development. A notable
difference in the two populations is the expression of genes corresponding to members of the
AP-1 network. The AP-1 network was validated to be critical for tumorigenesis in SCLC.
Barcoded SCLC xenografts and chemoresistant xenografts belonging to two SCLC subtypes
were generated. scRNA-seq revealed increased transcriptomic plasticity following chemotherapy
treatment in SCLC-A xenografts but not SCLC-N xenografts. The Cancer Testis Antigens
PAGE5 and GAGE2A were identified and validated as mediators of chemoresistance in SCLC.
This work represents the first application of genetic barcoding in SCLC and identifies actionable
drug targets for future development.
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Chapter 1: Introduction
Small cell lung cancer (SCLC) is a devastating disease characterized by a 5-year survival rate of
only 6%1. The majority of patients (75%) present with extensive stage disease at diagnosis, and
survival for these patients is generally under 1 year2,3. Given the usually extensive stage disease
at diagnosis, surgical resection is rare, and the majority of patients are treated with first-line
platinum agents such as cisplatin or carboplatin and etoposide, a topoisomerase, as well as PDL1 inhibitor, regardless of PD-L1 status4,5. The recent addition of a PD-L1 inhibitor improved
survival about two months in clinical trials6, however advances in therapeutics are critically
needed. Patients who present with brain metastasis may receive cranial radiotherapy. While
initial response to chemotherapy generally seems promising, the majority of patients will rapidly
acquire resistance and relapse within months (Figure 1A)3. After relapse, several options exist
for secondary treatment, however, few patients see a benefit after a few months, and the majority
then receive palliative support5. The therapeutic options for SCLC are rarely targeted or curative
and the grim outlook for patients with SCLC has remained largely unchanged in the last 60
years2,3.
SCLC is surprisingly uniform in genetic alterations driving the disease. Nearly all patients have
functional inactivation of the tumor suppressors RB1 (93%) and TP53 (100%) (Figure 1C)7.
Both critical tumor suppressors, RB is a canonical cell cycle regulator, and transcriptionally
regulates the transition between G1 and S phase. The loss of RB in cancer often leads to
dysregulation of the cell cycle8. RB has also been found to act as a transcriptional regulator of
oncogenic pathways. RB deactivates pluripotency genes SOX2 and OCT4, so when RB is lost in
cancer, pluripotency networks are de-repressed and lead to a plastic, stem cell like state (Figure
1B)9.
1

Figure 1: Clinical and genomic presentation of SCLC.
A: Radiograph of a patient with SCLC at diagnosis with a lesion circled in red. At a responding stage,
the lesion is not present. At the relapsed stage, disseminated metastasis can be observed. From
Stewart et al., 2020. B: RB binds to and activates pluripotency genes. ChIP data showing RB (blue)
binding sites on the Sox2, Oct4, and Mcm7 genes. From Kareta et al., 2015.C: Variant allele
frequency of commonly altered genes in SCLC. Gene names are indicated in rows and individual
patients in columns. A colored rectangle indicates a mutation in that gene. P53 and Rb on the first and
second rows, respectively, are mutated in almost 100% of patients. Other commonly altered genes
indicated are NOTCH family members. D: Copy number alterations frequently observed in SCLC.
Blue variants represent deletions in genes such as Rb and P53, and red indicates gene amplifications.
Commonly amplified in this data set are MYC family genes. From George et al., 2016.
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The expression of SOX2 has been implicated in SCLC, where it acts as a transcription factor, and
acts in an oncogenic fashion by regulating key SCLC pathways10-12. In addition to the derepression of SOX2 driven by loss of RB, SOX2 has also been found to be amplified in around
30% of patients, and is required for tumorigenesis (Figure 2A, B, C)10,11,13. TP53 is implicated in
the majority of human cancers. It is a transcription factor that acts in response to cellular
stressors such as DNA damage, when it works to determine the cell’s response. Loss of P53 in
cancer can lead to an accumulation of DNA and cellular damage and mutations14. Also common
are alterations in MYC. Patients frequently have amplification of MYC, MYCL1, or MYCN7. The
expression of MYC genes in SCLC are mutually exclusive, and have a role in mediating SCLC
subtype and chemoresistance7,11,13,15-18. NOTCH family members are frequently implicated in
SCLC pathogenesis. Around 25% of patients have genomic alterations in NOTCH 7. In SCLC,
NOTCH expression is downregulated, which allows for neuroendocrine differentiation. NOTCH1
is epigenetically suppressed in the SCLC-A type, which allows for the activation of ASCL119,20.
Additionally, the NOTCH ligand DLL3 is highly expressed in SCLC, and is correlated with
ASCL1 expression and subtype, with highest expression in the SCLC-A type21,22. Alterations in
NOTCH signaling may also play a role in the plasticity between SCLC subtypes11,16,18. A 2017
report found that in neuroendocrine SCLC, NOTCH signaling acted as a pro-tumorigenic factor,
while in non-neuroendocrine SCLC, NOTCH signaling acted as a tumor suppressive factor20. In
MYC-driven SCLC, MYC activates NOTCH signaling, which drives the SCLC-A
(neuroendocrine) to SCLC-N (non-neuroendocrine) subtype transition16.

3

Figure 2: Sox2 is frequently amplified in SCLC and is required for tumorigenesis
A: Genetic amplification and deletions in SCLC. SOX2 (red, boxed) is frequently amplified. B:
Expression of Sox2 in normal and SCLC tissues. C: FISH analysis of Sox2 copy number. Red is the
Sox2 probe and green is the centromeric probe. From Rudin et al., 2013 D: SOX2 is critical for tumor
formation in a mouse model of SCLC. The gray bar indicates tumors from mice with biallelic deletion
of SOX2, which form significantly fewer tumors than mice with at least one copy of SOX2. Mice with
deletion of SOX2 survive significantly longer than mice with expression of SOX2. From Voigt,
Wallenberg et al., 2021.
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Historically, SCLC has been thought of as being subtyped as either “classic” or “variant”.
Classic SCLC generally has more neuroendocrine features than variant, and they behave
differently in cell culture, with the neuroendocrine-high SCLC-A lines growing more as
organized spheres, and the SCLC-N subtypes growing as less organized clusters, or occasionally,
adherent cell lines23. As genomics techniques have progressed, SCLC has been able to be
subtyped based on the genomics of the tumor. Tumors can be subtyped based on expression of
ASCL1, NEUROD1, POU2F3, and YAP1 (Figure 3A, B, C)24. The subtypes differ in their
molecular, histological, and phenotypic characteristics, both in culture and in the clinic.
Historically called “classic” SCLC, the majority of patients with SCLC have ASCL1-driven
disease (or SCLC-A). SCLC-A tumors generally arise from pulmonary neuroendocrine cells and
display neuroendocrine features and gene expression, and are high in MYCL, SOX2, and
DLL311,22,24. NEUROD1-driven tumors (SCLC-N) are also neuroendocrine, although to a lower
degree than SCLC-A. They have lower expression of SOX2, and express MYC instead of MYCL,
and were historically classified as “variant” due to their distinct histology11,22,24. The YAP1driven tumors (SCLC-Y) are more rare and seem to exist in the same lineage as SCLC-A and
SCLC-N, as indicated by some tumors showing plasticity between the three16. SCLC-Y is nonneuroendocrine and occasionally has wild-type expression of RB24. Tumors that are SCLC-Y
may have histological features that contain the more “variant” or combined cell morphology22.
The final subtype, SCLC-P (POU2F3 driven) is much more rare than the other three. These
tumors are generally non-neuroendocrine and express more of the markers of tuft cells,
suggesting SCLC-P tumors arise from a separate lineage than SCLC-A, SCLC-N, or SCLC-Y,
which primarily have pulmonary neuroendocrine cells as their cell of origin16,24. There is ample
evidence that these subtypes are not static in nature. Patient histology often demonstrates
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separate areas of SCLC-N and SCLC-A within the same patient sample22,24. Additionally, cell
culture and mouse models have demonstrated subtype switching of tumors (Figure 3D,
E)11,16,18,25.
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Figure 3: SCLC can be subtyped in to four plastic molecular subtypes
A: Transcriptomic data of SCLC samples and cell lines showing clustering by the expression of one
of four factors: ASCL1, NEUROD1, POU2F3, and YAP1. Subytpes also stratify by neuroendocrine or
non-neuroendocrine status. B: Proportion of patient samples belonging to each subtype. Most patients
have tumors that are SCLC-A, followed by SCLC-N. C: Expression of SCLC associated genes MYC,
BCL2, and DLL3. Expression level of these genes is dependent on subtype, indicating a distinct
phenotype for each subtype. D: Pseudotime trajectory based on scRNA-seq of Myc driven SCLC
demonstrates transition from SCLC-A to SCLC-N, and SCLC-Y. This coincides with a switch in Myc
expression and upregulation of Notch family members. From Ireland et al., Cancer Cell 2020. E: Myc
expression drives plasticity in SCLC subtypes from SCLC-A to SCLC-N. Notch pathways are also
upregulated in this switch, and a change in neuronal pathways is observed as the subtype switches.
From Patel et al., Science Advances, 2021.
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Despite the almost uniform loss of RB and P53, there still may be other genetic drivers of SCLC.
In order to better understand the genetic drivers of SCLC, Peifer et al (2012) did SNP array
analysis, exome sequencing, and genome sequencing of tumors and cell lines. They confirmed
common loss of RB, gain of SOX2, FGFR1, MYCL, and MYCN. The MYC family member
amplifications were mutually exclusive. Additionally, they identified a set of likely driver genes
for SCLC (TP53, RB1, PTEN, CREBBP, EP300, SLIT2, MLL, COBL, and EPHA7)26. To
investigate the mechanism of tumor progression and identify somatic drivers of SCLC,
McFadden et al (2014) performed whole exome sequencing on matched tumors and metastases
from SCLC mouse models. They found frequent copy number variants (CNVs), many of which
have an impact on MycL and the Notch pathway. Chromosome 4 genomic rearrangements were
common, which may lead to MycL and Nfib amplification. These rearrangements are similar to
ones seen in the human homologues in human cases of SCLC. Mutations in Pten and members
of the Pten pathway were very common in their analysis. Alterations in Pten signaling may be a
mechanism of tumor promotion, and loss of Pten signaling promotes tumor progression. To
understand heterogeneity, they compared DNA rearrangements and point mutations in primary
tumors and metastasis from individual mice, and showed that metastases had a greater number of
mutations with a high allelic fraction, indicating that metastasis is a bottleneck event. In clonal
analysis, most tumors had 2-5 individual tumor subclones, and in some cases, multiple
metastases from different tumor subclones were seeded to the site of metastasis27. Using
proteomic profiling, Tripathi et al sought to understand chemoresistance in SCLC Patient
Derived Xenografts (PDX) and cell lines. In a chemoresistant cell line, they found significant
increase in the cell surface proteome, indicated by an abundance of proteins associated with
cytoskeletal reorganization and cell adhesion. They focused the analysis on the five most
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differentially expressed proteins: EGFR, JAG1, ITGB1, EPHA2, and MCAM. In PDX, MCAM
was increased in the chemoresistant tumors, and these tumors had higher EMT markers.
Knockdown of MCAM in culture did not impact EMT markers but did decrease cell proliferation
and colony formation. Cells with a knockdown of MCAM were also more sensitive to
chemotherapy and had an increase in pro-apoptotic proteins. MCAM overexpression in cell
culture led to an increase in cell survival after chemotherapy. This is due to SOX2-dependent
regulation of the PI3K/AKT pathway, which is upregulated in chemoresistant calls and acts as a
regulator of MCAM. Chemoresistant cells also had a lower metabolic rate, which indicates a
shift towards glycolysis in these cells28.
Cells in a single tumor are often phenotypically different from one another and contribute
differentially to the tumor dynamics, a phenomenon known as intratumoral heterogeneity
(ITH)29. ITH is perhaps best demonstrated by the classic example of cancer stem cells (CSC),
which generally make up a minority of the bulk of a tumor, yet they are the cells most directly
responsible for tumor growth and maintenance30. ITH has an impact on response to therapy,
particularly in SCLC, as demonstrated by patients’ almost full response to chemotherapy, only to
have extensive disease re-occur rapidly3,31. Clearly, there exists a population of cells are either
inherently resistant to therapy, or have the plasticity to adapt and become resistant when faced
with therapy3. Understanding ITH is critical to developing new, effective therapeutics for SCLC.
Armed with the knowledge of which populations contribute to tumor dynamics, we can design
intelligent therapeutics to address the most aggressive cellular populations. Understanding ITH is
critical to developing and targeting new therapeutics, and ITH has been studied in many tumor
types, but because of the lack of SCLC samples in the TCGA, SCLC has been excluded from
large-scale analyses of ITH32.
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Tumor heterogeneity has been observed in SCLC, and in recent years, there have been several
groups that have worked to understand the origins, evolution, and functional impact of
heterogeneity in SCLC using genomics, transcriptomics, and proteomics. Yang et al (2018)
sought to understand the origins of tumor heterogeneity depending on cell type of origin in
mouse models of SCLC. They used the Rblox/lox, p53lox/lox, p130lox/lox (RPR2) mouse and initiated
tumors using a general Cre adenovirus (CMV-Cre) and a CGRP-Cre adenovirus, which initiates
tumors in just the neuroendocrine cells. The tumors from the CMV-Cre mice were generally high
in Nfib, and were metastatic. Tumors from the CGRP-Cre mice required a higher concentration
of virus to initiate, and to form metastatic tumors, and metastatic events were not reliant on Nfib.
The ability to form metastases with and without the expression of Nfib indicates multiple
metastatic pathways that the tumors could take. They used a multi-color reporter mouse bred
with the RPR2 model to investigate the mechanisms of metastasis in their mouse models. The
majority of metastases came from a single primary tumor and were clonal, indicating not all cells
in a tumor have an equal likelihood of metastasis. In the transition from primary to metastatic
lesion in the CMV-Cre mice, there were widespread changes in gene expression in genes related
to neuronal differentiation and cell cycle. In the CGRP-Cre mice, there were few gene expression
changes between primary and metastatic tumors. The CGRP-Cre tumors had higher expression
of neuroendocrine genes, and the CMV-Cre tumors higher expression of epithelial cell markers.
Overall, different cells of origin in the CGRP-Cre initiated tumors and the CMV-Cre initiated
tumors led to heterogeneity in genomic profile, metastasis mechanism, and histology33. To
understand the impact of Myc and Nfib on tumor heterogeneity and chemoresistance, Bottger et
al (2019) used three common mouse models of SCLC – loss of Rb and p53 (RP); loss of Rb, p53,
with MycL amplification (RPM); and loss of Rb and p53 with an Nfib overexpression (RPF).
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They found heterogeneity in the histologic features of each of these three tumor models and the
percentage of lesions that were bronchiolar or alveolar. MycL promoted lesions that were
neuroendocrine and high in Ascl1. Regions in all models that were sensitive to chemotherapy
were high in CDH1, and after chemotherapy, there was an increase in CDH1-low lesions,
underlying cisplatin resistance. The proportion of the tumors that were CDH1-high and sensitive
to chemotherapy differed by mouse genotype. After cisplatin treatment, there was a shift to a
more epithelial signature, and changes in metabolism indicating a decrease in proliferation in
response to cisplatin treatment25. Further investigating the link between Myc and tumor
heterogeneity, Ireland et al (2020) used both the RPR2 model and a Myc overexpression mouse
model (Rblox/lox, p53lox/lox, LSL-MycT58A; RPM) combined with multiple timepoint scRNA-seq to
evaluate Myc signaling in lineage fate determination. Early lesions from both models are ASCL1
high with classic neuroendocrine markers. In later lesions, the RPR2 model (generally high in
MycL) maintained the ASCL1, high neuroendocrine subtype, and the RPM model showed a
decrease in neuroendocrine markers. Pseudotime analysis reconstructed a lineage showing that
cMyc can convert early ASCL1-high lesions to the SCLC-N or SCLC-Y subtype (Figure 3D).
They validated this in primary culture of early tumor lesions from the RPM model, which start
off as SCLC-A and transition to SCLC-N with high expression of non-neuroendocrine markers
like NOTCH. Conversely, cells from the MycL high RPR2 tumors remain as SCLC-A in culture.
Overexpression of cMyc in SCLC-A cells in culture converted cells to neuroendocrine-low
SCLC-N and later to SCLC-Y. NOTCH signaling plays a role in the transition from SCLC-A to
SCLC-N, and they showed that cMyc is directly responsible for the change in NOTCH signaling.
Interestingly, if a Cre specific to AT2 or club cells was used to initiate tumors, the resulting
tumors are SCLC-P, which is rarely the case in tumors resulting from neuroendocrine cells.
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Therefore, the SCLC-P subtype arises from a different cell of origin than the other subtypes, and
is driven by cMyc16. To study the mechanistic link of cMyc or MycL expression in determining
SCLC subtype, Patel et al (2021) used transcriptomic data to associate networks with MycL or
cMyc expression (Figure 3E). They found distinct transcriptomic profiles associated with either
MycL or cMyc. In representative cell lines, ATAC-seq found MycL and cMyc had different DNA
binding profiles, which suggests differential regulation of transcriptomes. All SCLC-N lines
were associated with c-MYC accessibility at NEUROD1 and all SCLC-A lines were associated
with MYCL accessibility at ASCL1. Intriguingly, c-Myc or MYCL had no association with the
expression of YAP1 or POU2F3. Overexpression of MYCL in an SCLC-N cell line did not
convert the line to SCLC-A, but led to an increase in neuronal genes. Depletion of cMYC in
SCLC-N did lead to downregulation of NEUROD1. Conversely, overexpression of cMYC in an
SCLC-A line led to a decrease in neuroendocrine markers of SCLC and more “variant”
histology, and trans-differentiated an SCLC-A line to an SCLC-N lineage. Bulk RNA-seq of
these cells showed an increase in epithelial genes and cMYC associated pathways. They also
found upregulation of the Notch pathway, which has been shown to negatively regulate ASCL1
expression18. Taken together, cMYC and MYCL are lineage determining factors that play a direct
role in activating transcriptomic networks including NOTCH and epithelial pathways that
characterize the SCLC-N or SCLC-A subtypes.
Given the importance of cMyc and MycL in SCLC, Grunblatt et al (2020) wanted to evaluate the
role of Mycn in SCLC. They developed a mouse model with deletion of Rb and p53, and
overexpression of Mycn (RPMYCN). RPMYCN mice developed tumors faster and had a much
lower median survival than the Rb and p53- loss driven mice (RP, MycL high). The majority of
the tumors from the RPMYCN mice were of the “classical” type by histology and had ASCL1
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expression by immunohistochemistry, although scattered regions of NEUROD1 and YAP1
positive cells existed. When Mycn is turned off in the tumors that formed in RPMYCN mice,
tumors regressed, indicating that tumors that start from a Mycn high population are reliant on
Mycn to continue to proliferate at as high of a rate, although they do eventually return. Both
RPMYCN mice and MYCN-driven patient derived xenografts (PDX) were more resistant to
cisplatin and etoposide treatment. To evaluate the regulation of MYCN on tumor dynamics, they
used RNA-seq and found a number of MYC target genes to be differentially expressed including
immune signaling pathways. This matches the phenotype seen in the RPMYCN mouse model, as
immune cells from the MYCN tumor model had a significant decrease in CD3 T-cells and
monocytes, as compared to cells from non-MYCN driven tumor models. Finally, using CRISPRCas9 sgRNA inactivation screens, they found that USP7 is responsible for maintaining MYCN
stability, and when USP7 is inhibited, there were decreased levels of MYCN. USP7 inhibition
also sensitized MYCN-driven PDX to cisplatin and etoposide15.
To investigate tumor heterogeneity before and after chemoresistance, Stewart et al (2021) used
circulating tumor cells (CTC)-derived xenografts isolated from tumor cells circulating in the
blood of patients who were both chemo-naïve and chemoresistant, combined with scRNA-seq.
The majority of the tumors were neuroendocrine, and most were high in ASCL1, even from
chemoresistant patients. Both MYC and MYCL were activated, and some tumors had mixed
expression of MYC and MYCL within a single tumor. Using the transcriptomic data, they
calculated an intratumoral heterogeneity (ITH) score for each tumor and found increased ITH
and an increased number of transcriptional clusters in PDX from patients who had
chemoresistance. Multiple resistance pathways were upregulated within single tumors, indicating
it is likely that multiple resistance pathways arise at one time. After treatment with cisplatin in
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PDX, EMT score increased and ASCL1 decreased, but they did not see an increase in
NEUROD1 expressing cells. This data indicates an increase in ITH after therapy and the ability
for tumors to arise multiple resistance pathways within a short period of time31. To understand
the spatial component to ITH, Rovira-Clave et al (2021) used epitope combinatorial tags
combined with multiplex ion beam imaging (EpicMIBI), which allows for tracking of barcodes
within the tissue in SCLC xenografts from an SCLC-N cell line (H82). EpicMIBI allows for the
identification and tracking of clonal populations of cells in their spatial position combined with
single-cell proteomic data. They observed heterogeneity in neuroendocrine and nonneuroendocrine states, as well as differences in epigenetic markers and vimentin expression
within a single xenograft. Non-neuroendocrine cells all cluster together, and based on clonal
analysis, have different growth patterns than the neuroendocrine cells. They saw that the rare
cells cluster near each other, indicating that heterogeneity is not equally distributed throughout
the tumor, and is instead located in subclonal “patches”. A minority of patches had loss of
PTEN, and these influenced the growth of their neighbor patches that still had wild-type PTEN.
Xenografts grown from cell lines do indeed form heterogeneous tumors, and the clonal patches
within the tumor have the ability to influence the behavior of nearby patches34. Given the very
limited access to human specimens, Chen et al. (2021) used autopsy samples and whole-exome
and transcriptome sequencing of patient samples to understand heterogeneity in human samples,
particularly metastatic and immune signatures. They found a high mutational burden and high
copy number variants (CNVs) present in all patients. They had access to both primary and
metastatic sites for the patients, so they were able to reconstruct a clonal lineage using CNV
analysis. Clonal heterogeneity was different depending on the patients but there were some
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signatures in common. In general anti-tumor immune markers were elevated in advanced tumors,
and stratified based on tumor subtype13.
Past work has shown that tumor heterogeneity does exist in SCLC, is plastic, and has a
functional impact on tumor growth and response to chemotherapy. However, there are a number
of remaining questions for SCLC tumor evolution. We have yet to investigate the very early
stages of tumor formation in SCLC, to understand what the source and drivers of tumor diversity
are (Figure 4). The understanding of how ITH arises are critical to designing therapeutics and
targeting the most aggressive populations (Figure 4). Furthermore, the tumor evolution studies
that have been done in SCLC, while incredibly useful, work on a pseudotime or retrospective
perspective, which is not temporally resolved.
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Figure 4: Theories of the development of ITH.
Understanding the origins and evolution of ITH is critical to uncovering targetable populations. This
figure presents three models for the development of ITH. The cancer stem cell model (A) in which
one self-renewing population can differentiate in to multiple clonal populations. The Clonal evolution
model (B), has a core differentiated population and one cancer stem cell that self-maintains. C
presents the plasticity model, in which there are multiple populations with self-renewal capacity.
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Historically, tumors have been sequenced using bulk RNA sequencing methods, however, this
masks the true contribution of individual populations and aggregates the signal from the entire
sample13,27. Single-cell RNA sequencing (scRNA-seq) has radically transformed our
understanding of ITH. The scRNA-seq studies that have been performed on SCLC tumors and
xenografts16,31,35 and other genetic profiling that have been used to generate pseudotime maps of
ITH in response to growth and chemotherapy13,16,18,25,27,31,34, while incredibly useful, do not
allow for the pinpointing of the populations critical for these tumor dynamics. Instead, it is
inferred from the populations identified in the screening. In recent years, genetic barcode lineage
tracing has emerged as a novel tool to trace individual clonal populations over time36-38. Genetic
barcode lineage tracing allows for the identification of individual cellular clones by inserting a
unique piece of DNA to serve as a “barcode” in to the genome of a cell using a retrovirus or
CRISPR sgRNA library39,40. As the cells divide, the barcode will be passed to the progeny,
allowing for a high-resolution tracing of individual clonal populations (Figure 5). Originally used
for tracing populations in hematopoiesis36,41, the barcodes integrated are stable over time in
vivo36 and are able to be detected with scRNA-seq41,42. Barcoding serves as a technological
advance on other lineage tracing methods such as fluorescence labeling30. Fluorescence labeling
is limited in the number of potential fluorophores, and the tracking of mutation rates does not
allow for a temporal component, since lineages must be reconstructed after heterogeneity has
already developed32,33,43.
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lineage dynamics
Figure 5: Overview of the barcoding system.
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The use of genetic barcode lineage tracing to understand tumor heterogeneity has exploded in the
last few years. It has now been used to understand cellular lineages and heterogeneity in a
number of cancer types including glioblastoma, breast, non-small cell lung cancer, leukemia, and
melanoma37,40,44-50. Often, integration of barcodes is lentiviral, often done along with a
fluorescent marker like a GFP37,44,45,48. In glioblastoma, genetic barcoding has been used in a
xenograft model to understand the cancer stem cell pool and chemoresistance. Lan et al (2017)
first barcoded primary cultured glioblastoma cells and performed serial xenografts to identify the
stem cell pool that is capable of tumor formation37. Neftel (2019) and Eyler (2020) both used
lentiviral barcoding to understand tumor heterogeneity in glioblastoma after chemotherapy.
Neftel identified for the first time the cellular states that simultaneously exist within a tumor, and
characterized the plasticity in cell states in glioblastoma45. Using barcoded tumor spheres, Eyler
focused on identifying lineages that were responsible for surviving targeted therapy. They were
able to identify the acquisition of copy number gains in direct response to receptor tyrosine
kinase inhibitor treatment in the clones that survived therapy44. Also using lentiviral barcoding,
Emert et al (2021) combined the barcode with RNA fluorescence in situ hybridization (FISH) in
melanoma cells in culture to identify cell states that lead to therapy resistance. They created two
populations with identical barcodes, one that got sequenced to profile the barcodes in a treatment
resistant population, and another that was molecularly profiled after using RNA FISH to isolate
populations corresponding to the barcodes of the surviving clones that were sequenced. They
identified multiple resistance pathways in response to therapy48. PRISM technology is a unique
application of barcoding, which allows for the multiplexing of lenivirally barcoded cell lines
from the cancer cell line encyclopedia (CCLE), can be used to assay several cell lines at once,
which can then be de-multiplexed after molecular profiling. It has been used to measure
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therapeutic vulnerabilities and metabolic changes in hundreds of cell lines at once, which would
be a tedious and near-impossible task without the ability to barcode the individual cell lines for
later identification51,52.
Another popular barcoding technique utilizes a CRISPR-Cas9-based barcode. In lung
adenocarcinoma, Guernet et al (2016) used CRISPR-Cas9 to edit their gene of interest, while
inserting a series of extra point mutations to serve as a heritable barcode. In this case, their
barcode was detectable by qPCR, which made understanding clonal dynamics more costeffective, but did not easily pair barcodes with large transcriptomic data40. Adaptable CRISPR
barcodes have the ability to not only label clonal populations, but also evolve over the course of
the disease to reconstruct a phylogenetic tree with higher resolution, and has been used in lung
adenocarcinoma xenografts and mouse models to understand tumor evolution and metastasis46,53.
Using a CRISPR-Cas9 approach, Rogers et al (2018) barcoded individual tumors in a mouse
model of lung adenocarcinoma by barcoding founder cells during tumor initiation to understand
the driver genes of tumor formation, but not necessarily subclonal lineages54. Recently, there has
been some interest in isolating clones in real time, after identifying the barcodes of the
populations of interest. ClonMapper combines barcodes and transcriptomic data that allows for
the identification and recovery of populations of interest. It has been used in melanoma cells in
culture, and has shown to be a powerful tool for understanding clonal dynamics in vitro47.
In SCLC, genetic barcoding has been performed twice, but has not been used in combination
with transcriptomic data, in a time-dependent manner, or to understand response to
chemotherapy. Spatial epitope barcoding has been used in a xenograft model using one SCLC-N
cell line to understand tumor architecture during tumor development34. Recently, a pre-print has
described the use of barcoding in a mouse model of SCLC to understand tumor initiation. Cells
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were barcoded at the point of tumor initiation, which will allow for the identification of the
alterations present in the cells able to form tumors using TUBA-seq, but does not allow for the
understanding of tumor evolution55. To date, genetic barcoding has not been used to understand
tumor evolution in a temporal manner, and has never been combined with a model of
chemoresistance.
We know that ITH is key to SCLC growth and metastasis, and that SCLC tumors are highly
plastic, and are able to adapt and overcome when faced with chemotherapeutic treatment.
Without an in-depth understanding of ITH, we are not able to develop the most effective
therapeutics for SCLC. The use of genetic barcoding and scRNA-seq in this work will allow us
to view the early origins of ITH in SCLC for the first time, and identify new cellular populations
and therapeutic targets to treat this disease.
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Chapter 2: Methods
2.1: Ethics statement
Mice were maintained according to the guidelines set forth by the NIH and were housed in the
Sanford Research Animal Research Center, accredited by AAALAC using protocols reviewed
and approved by our local IACUC.
2.2: Generation and validation of barcoding libraries
2.2.1: Cloning of the barcoding libraries
To clone the retroviral barcoding library, a CAG-GFP retroviral plasmid was used as a backbone
(gift from Fred Gage, Addgene plasmid # 16664 ; http://n2t.net/addgene:16664 ;
RRID:Addgene_16664)56. A poly-A sequence was subcloned from TetO-FUW-sox2, a gift from
Rudolf Jaenisch (Addgene plasmid # 20326 ; http://n2t.net/addgene:20326 ;
RRID:Addgene_20326 )57, to the 3’ end of the GFP at the PmeI site using InFusion Cloning
(TaKaRa) and screened with PCR and restriction digests. DNA oligos containing the barcode
sequence were ordered from Eurofins and annealed by heating to 95 degrees C for five minutes
and allowed to cool to room temperature over the course of several hours. The CMV-GFP-polyA
plasmid was digested at PmeI and HindIII (added in the polyA cloning step), and the annealed
barcode was inserted by InFusion cloning (TaKaRa) at the 3’ end of the polyA and 5’ end of the
GFP sequence. 40 of the initial colonies were screened for presence of the barcode via PCR, and
four of those were further validated to contain the barcode using Sanger sequencing. All 40
colonies screened by PCR contained the barcode, and all four colonies screened by Sanger
sequencing contained unique barcodes. Once presence of the barcode was confirmed in a number
of colonies, the cloning product was transformed and plated to grow on five 15-cm plates of LB
agar. Following overnight growth, all colonies were collected and pooled by flushing the plates
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with pre-warmed LB broth. Plasmid libraries were maxiprepped and the product was pooled and
purified. Gamma-Retrovirus was produced by co-transfection of 293Ts with the barcoding
retrovirus and retroviral packaging plasmid pCL-Amph. Retroviral supernatant was collected 48
and 72 hours after transfection and concentrated using the TaKaRa Retro-X concentrator.
To clone the AAV9-r26-GFP-BC CRISPR plasmid, a sgRNA targeted to Rosa26 was subcloned
from pU6-sgRosa26-1_CBh-Cas9-T2A-BFP, a gift from Ralf Kuehn (Addgene plasmid # 64216
; http://n2t.net/addgene:64216 ; RRID:Addgene_64216)58,59 and inserted in to the AAV-KPL
backbone (AAV:ITR-U6-sgRNA(Kras)-U6-sgRNA(p53)-U6-sgRNA(Lkb1)-pEFS-Rluc-2ACre-shortPA-KrasG12D_HDRdonor-ITR (AAV-KPL), a gift from Feng Zhang (Addgene
plasmid # 60224 ; http://n2t.net/addgene:60224 ; RRID:Addgene_60224))60 at SacI and MulI
using InFusion cloning (TaKaRa), and screened for presence of the insert using PCR and Sanger
sequencing. Left and right homology arms to Rosa26, as well as a polyA signal were subcloned
from pR26 CAG/GFP Dest, a gift from Ralf Kuehn (Addgene plasmid # 74281 ;
http://n2t.net/addgene:74281 ; RRID:Addgene_74281)58,59 in to the AAV9-r26 plasmid at PmlI.
The barcode library, attached to a GFP was ordered from ThermoFisher’s GeneArt program, and
was inserted in to the AAV9-r26 plasmid at PmlI and BamHI via InFusion cloning. After the
first 30 colonies were screened for insertion of the barcode by restriction digest, PCR, and
Sanger sequencing, chemically competent cells were transformed with the plasmid pool and
plated on ten 10-cm LB plates. After overnight growth, all plates were washed with pre-warmed
LB and the pooled colonies were maxiprepped. The AAV9-r26-GFP-BC plasmid was made in to
AAV9 at the University of Michigan Viral Vector Core.
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2.3: Validation of barcode diversity in barcoded cells
To profile the diversity in the barcode pools, targeted amplicon sequencing was performed on the
barcode region. PCR was used to amplify the barcode and add partial adaptors for Illumina
sequencing. The minimal number of cycles needed to amplify the barcode region was used to
minimize the risk of introducing variants, or over-saturate the sample with a limited number of
barcodes that had been disproportionately amplified. Samples were sequenced on an Illumina
platform at Genewiz. The targeted amplicon sequencing of the barcodes was trimmed and QC
performed via CutAdapt. GREP was used to identify barcodes and export them to R Studio for
analysis. In R studio, the true number of barcodes was determined by using the number of PCR
cycles to backtrack diversity, combined with the PCR error rate, determined by the number of
PCR errors in the constant region of the barcode. Chao2 modeling was used to estimate the
number of barcodes in the pool.
2.3.1: Doubling time assays to determine fractional overlap of barcodes
In order to ensure sufficient overlap in barcodes between the “pre-growth” sample and
xenografts, I sought to determine the optimal number of doublings before sufficient overlap in
two independent samples was observed. 1,600,000 cells were seeded and barcoded using the
CAG-GFP-BC retrovirus and a spinfection at 940xg for 2 hours. At each doubling for five
doublings following spinfection, one well of cells was harvested and split in to two. The barcode
region was amplified off of the cDNA, and partial adapters for Illumina-based sequencing was
added. Amplicon sequencing was performed at Genewiz (South Plainfield, NJ) using an
Illuminia miSeq platform. The barcodes were analyzed using a custom R script after trimming
and QC via CutAdapt. To verify the results of the barcode sequencing, computational modeling
was used. I simulated the same doubling time experiment 1,000 times using a custom R package.
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Based on the results of the sequencing, modeling, and previously published work 41, three
doublings after barcoding gives sufficient overlap between two independent samples and will be
used to generate the barcoded xenografts.
2.4: Mouse protocols
2.4.1: In vivo model
The well-characterized Rblox/lox, p53lox/lox, p130lox/lox SCLC mouse model 61 was bread to the
H11lox-stop-lox-Cas9 mouse62 model (Jax #026816) to generate the RPR-Cas9 mouse used in this
work. Tumors were initiated by intratracheal injection with Ad-CMV-Cre (Baylor Viral Vector
Core) to delete the Rb, p53, and p130 loci, and induce expression of Cas9. At one month
intervals for five months after tumor initiation, the AAV9-r26-GFP-BC virus was delivered to
separate cohorts of mice via intratracheal injection to barcode the forming tumors at the Rosa26
locus using the CRISPR-Cas9 system. Mice were euthanized at one month intervals after their
Ad-CMV-Cre injection, up to six months, or when they became moribund according to
institutional IACUC guidelines. Two mice received chemotherapy at 5 mg/kg cisplatin and 10
mg/kg etoposide on day one, and 10 mg/kg etoposide on days two and three, repeated for three
weeks, and were allowed to progress until they were moribund15.
2.4.2: Xenografting of barcoded tumors
H209 and H82 SCLC cell lines were barcoded with the rCMV-GFP-BC retrovirus by spinfection
at 940xg for 2 hours. Each barcoded line was allowed to double three times, to ensure overlap in
barcodes in the cells sampled and cells used for xenografting. Immediately prior to xenografting,
a portion of the cells were removed to generate the single-cell RNA sequencing library (“pregrowth” sample). To make the xenografts, 2500 cells were mixed in a 1:1 ratio with matrigel
(Corning Life Sciences) and injected into the hind flank of NOD-SCID mice. Xenografts were
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measured daily after the tumors were palpable by hand in the hind flank. After xenografts
reached 3 cm3 total volume, mice were euthanized and the xenografts harvested. Tumors were
dissected, dissociated, and a portion of the cells were used for single-cell RNA sequencing (“prechemotherapy” sample). The remainder of cells were mixed in a 1:1 ratio with matrigel and
injected in to a new NOD-SCID mouse. The mice that received these serial xenografts received
chemotherapy at 5 mg/kg cisplatin and 10 mg/kg etoposide on day one, and 10 mg/kg etoposide
on days two and three, repeated for three weeks after tumors were palpable to generate
chemoresistant xenografts 15. When these mice reached a total tumor burden of 3 cm3, they were
euthanized, and the tumors were dissociated and used to generate single-cell RNA sequencing
libraries (“post-chemotherapy” sample).
2.5: Tumor profiling using single cell RNA sequencing
2.5.1: Tissue processing and library preparation
The “pre-growth” samples from the xenograft model were prepared for scRNA-seq according to
the 10X Genomics protocols. After xenografts reached a cumulative volume of 3 cm3, mice were
euthanized and tumors dissected. The MACS (Miltenyi Biotec) human tumor dissociation kit
was used to digest the tumors, and cells were prepared for scRNA-seq using the 10X Genomics
protocols.
After the RPR-Cas9 reached their endpoint, they were euthanized via cervical dislocation and
lungs and livers were harvested. Tissues were prepared for flow cytometry according to the 10X
Genomics protocols, using the MACS mouse tumor dissociation kit. After dissection, the lungs
and livers were sorted for GFP+ cells, which are the barcoded population, and cells were
prepared for scRNA-seq according to the 10X Genomics protocol. Tumors were microdissected
from three mice by cutting out one tumor lesion, which was sequenced without undergoing
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FACS to capture the stromal and microenvironment cells. A 10X Genomics Chromium
Controller was used for the library preparation of all tumors.
2.6: Tumor Histology
One lobe of the lung and one lobe of the liver from each of the RPR-Cas9 mice were taken for
histology to verify the presence of tumors in this sample. Samples were fixed in 4%
paraformaldehyde for 15 minutes and transferred to 30% sucrose for 24-48 hours. The samples
were then embedded and cryosectioned before staining. Tumors were stained for GFP and Cas9
to confirm that the barcoding system was successfully induced by the Adenovirus induction of
Cas9 expression and AAV9 induction of GFP expression.
2.7: Informatics approach
The scRNA-seq data was initially filtered, trimmed and aligned via 10X Genomics CellRanger
program. CutAdapt was used to extract the barcode sequences. Low quality cells were filtered
out using Seurat, and clustering and psdudotime analysis was also performed in Seurat. The final
data was visualized with Loupe.
2.8: Validation of candidates identified via scRNA-seq
2.8.1: Expression of PAGE5 and GAGE2A in chemotherapy treated cells
An alamar blue assay was used to determine the IC50 value of cisplatin and etoposide in H82
and H209 cell lines. Cells were seeded in 96 well plates and treated with either drug, with
concentrations spanning three orders of magnitude. Cellular viability was assessed daily via
Alamar Blue. The IC50 for Cisplatin was determined to be 2.876 uM. The IC50 for etoposide
was determined to be 0.110 uM. These values were used for the resulting experiments. SCLC-N
lines H29 and H82, and SCLC-A lines H1836 and H209 were treated with cisplatin and
etoposide at the IC50 values for three days at cycles resembling the in vivo chemotherapy
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treatment (Cisplatin and etoposide day 1, etoposide only days 2 and 3). Cells were harvested ono
days two and three and RNA was extracted following the Trizol (Ambion Biosciences) protocol,
and RNA was converted to cDNA using the NEB ProtoScript Reverse Transcriptase Kit.
Expression levels of PAGE5 and GAGE2A were quantified via qPCR.
2.8.2: Knockdown of PAGE5 and GAGE2A and response to chemotherapy
shRNAs targeting PAGE5 and GAGE2A (Table 1) were designed using pSicoligoMaker3
(Ventura lab, https://bitbucket.org/theclipper/psicoligomaker3/src/master/). shRNA oligos were
cloned in to the lentiviral backbone pSicoR, a gift from Tyler Jacks (Addgene plasmid # 11579 ;
http://n2t.net/addgene:11579 ; RRID:Addgene_11579) 63. The pSicoR-shPAGE5 and pSicoRshGAGE2A were made in to a second-generation lentivirus using pMD2.G and psPAX2 as
packaging plasmids, and concentrated overnight using the TaKaRa Retro-X retroviral
concentrator. SCLC-N lines H29 and H82, and SCLC-A lines H209 and H1836 were infected
with pSicoR-shPAGE5 or pSicoR-shGAGE2A and sorted by GFP expression using the BD
FACS Jazz. Knockdown of PAGE5 and GAGE2A expression was validated in the sorted cells
with qPCR. To generate a double-knockdown, the sorted cells were infected with the reciprocal
virus and expression of both PAGE5 and GAGE2A was assessed via qPCR. The single- and
double- knockdown cells were used to generate xenografts to investigate the dependence of the
chemoresistance phenotype on PAGE5 or GAGE2A expression. 150,000 cells were mixed in a
1:1 ratio with GelTrex (Gibco) and injected in to the hindflank of NOD-SCID mice. Due to
supply chain disruptions, a switch from Matrigel to GelTrex was necessary, however they both
function the same way in providing some extracellular matrix to aid in xenograft injection.
Tumors were allowed to grow until a cumulative volume of 3 mm3 was reached, at which point
mice were euthanized and the tumors kept for histology to validate the knockdown of PAGE5
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and GAGE2A. Half of the mice were treated with chemotherapy at 5 mg/kg cisplatin and 10
mg/kg etoposide on day one, and 10 mg/kg etoposide on days two and three, repeated for three
weeks after tumors were palpable. In culture, the shPAGE5, shGAGE2A, and double knockdown
cells were treated with the IC50 value of cisplatin and viability was assessed via Annexin V and
propidium iodide staining by flow cytometry (Biolegend APC Annexin V Apoptosis Detection
Kit).
2.8.3: Overexpression of PAGE5 and GAGE2A
GAGE2A and PAGE5 overexpression retroviruses were generated by amplifying the transgenes
from SCLC cell lines and cloning them in to the CAG-GFP retroviral backbone. H29, H82,
H1836, and H209 cells were transfected with either the rCAG-PAGE5-GFP or rCAG-GAGE2AGFP vectors by spinfection with concentrated virus at 940xg for two hours. Transduced cells
were treated with the IC50 value of cisplatin, etoposide, or cisplatin and etoposide assessed for
response to chemotherapy by Annexin V and propodium iodide staining, and efficiency of
overexpression assessed by qPCR.
2.8.4: Knockdown of the AP-1 pathway via overexpression of dominant-negative Jun
To inhibit the AP-1 complex, cJun was knocked down by transfection with a dominant-negative
cJun construct. This is a common method for inhibiting the formation of the Jun/Fos AP-1
complex 64,65. pMIEG3-JunDN was a kind gift from Alexander Dent (Addgene plasmid # 40350
; http://n2t.net/addgene:40350 ; RRID:Addgene_40350) 64. H82, H29, H1836, and H209 SCLC
cell lines were transfected with pMIEG3-JunDN using Lipofectamine 3000. Upon visual GFP
detection, cells were sorted using FACS for GFP expressing cells. Cells were seeded in to 6 well
plates for a soft agar colony formation assay. Briefly, 0.8% Seaplaque agar (Lonza) was used as
a bottom layer and 10,000 cells per well were seeded in 1.2% agar in the top layer. Plates were
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fed with full RPMI as needed to prevent drying out. 10 days after seeding, colonies were
observed by eye and the plates were stained with 0.001% crystal violet for one hour, and plates
were photographed. The number of crystal violet colonies stained was quantified with a custom
CellProfilier script.
2.9: Analysis of PAGE5 and GAGE2A expression in human SCLC biopsies
2.9.1: Ethics statement
The staining and scoring, and well as storage of the data for all human specimens was approved
by the Sanford Health Institutional Review Board.
2.9.2: Staining of human biopsies
Human SCLC biopsies were obtained from the Sanford Health Biobank. Slides were stained with
anti-PAGE5 (Invitrogen PA5-50470) or anti-GAGE2A (Aviva Systems ARP64957-P050).
Stained slides were scanned using an Apereo AT2 slide scanner. Three independent researchers
viewed and scored the scanned slides based on positivity, distribution, and intensity of staining.
Positivity was a binary score, with the sample earning a positive score from any singular positive
cell. Distribution was scored on a 0-3 scale: 0 for 0-5% of the sample staining positively, 1 was
assigned to samples 6-30% positive, 2 for samples 31-60%, and 3 for samples more than 60%
positive for PAGE5 or GAGE2A. For staining intensity, a score 0-3 was assigned. 0 for samples
with no PAGE5 or GAGE2A staining, 1 for samples with light staining, 2 for samples with
moderate staining, and 3 for samples with intense staining.
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Name
Retroviral_PolyA

Forward
tgtacaagtaagtttaaacAAGCTTctgtgccttctagttgccagc

Reverse
gaggttgattggtttccatagagcccaccgcatc

Retrivral_Barcode_Oligo tgtacaagtaagtttaaacaagtttGTACAAGTAANNATCNNGAT gaaggcacagAAGCTTTTTACANNGTTNNACCNNTTTSS
SSAAANNGGTNNAACNNTGTAAA
ATCNNGATNNTTACTTGTACaa
AAV9_R26_gRNA
cggccgcacgcgcatgtgagggcc
ttctctgtggtgacaaaaaagcacc
AAV9_R26_LHDR

ttctcaggtaaccacgcggcaggccctcc

ccgctcggtccgcacgtgctagaaagactggagttgcagatcac

AAV9_R26_RHDR

cagtctttctagcacgtgggggatccactagttctagagc

ccgctcggtccgcacagggcatcagatcccattacaga

AAV9_BC_amp

cagtctttctagcacgtgGTGATGGTGAGCAAGGGCG

tagaactagtggatcGTACGACTTGGATCCCTCACTGG

Retroviral_miSeq

GACTGGAGTTCAGACGTGTGCTCTTCCGATCTaccttcca
gggtcaaggaagg
GACTGGAGTTCAGACGTGTGCTCTTCCGATCTaggctgat
cggccgc
CGAGGCGGCCGGATCTTAACACTGTGATTGCTTTTCA
CCTTCTTCAGGC
CGAGCCGGCCGGATCCTATAGTTGCCCTTCACCTGCTT

GAGE2A_qPCR

ACACTCTTTCCCTACACGACGCTCTTCCGATCTgagctg
tacaagtaagtttaaacaagtttGTACAAG
ACACTCTTTCCCTACACGACGCTCTTCCGATCTgcatgg
acgagctgtacaagg
ATTCGCTAGCGGATCGCCACCATGAGTTGGCGAGGAA
GATCG
ATTCGCTAGCGGATCGCCACCATGAGTGAGCATGTAA
CAAGATCCCA
TGAGTTGGCGAGGAAGATCG

PAGE5_qPCR

TGATGTCAGGGAGGGGACTC

TTGGGGTCTGAACTACCTTCAA

shPAGE5_Oligo_1

ggagaaaagccttgttTGGAACCACCAACTGATAATTTCAA ggatcctagtactcgaGAAAAAAGGAACCACCAACTGATA
GAGAATTATCAGTTGGTGGTTCCTTTTTTC
ATTCTCTTGAAATTATCAGTTGGTGGTTCCA
ggagaaaagccttgttTGCAGTTCAGTGATGAAGTTTCAAG ggatcctagtactcgaGAAAAAAGCAGTTCAGTGATGAAGT
AGAACTTCATCACTGAACTGCTTTTTTC
TCTCTTGAAACTTCATCACTGAACTGCA
GTGATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACG
GCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCA
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTA
CCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTT
CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCG
AGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCA
CAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAG
GACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGAC
AACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGA
GTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGGTACAAGTAAnnATCnnGATssAAAnn
GGTnnAACnnTGTAAAACGACGGCCAGTGAGGGATCCAAGTCGTAC

AAV9_miSeq
GAGE2A_OE_Cloning
PAGE5_OE_Cloning

shGAGE2A_Oligo_1
AAV9_BC_Oligo

Table 1: List of primers and oligos used.
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TCCCCTTCTTCAGGTGTTGC

Chapter 3: Generation and Validation of Barcoded Tumors in situ
3.1: Validation of the barcoding AAV
The AAV9 construct was designed to deliver all components of the CRISPR-Cas9 homology
directed repair (HDR) function, with the exception of Cas9, as it is already expressed in the
mouse lungs upon induction with Cre adenovirus. AAV9 has adequate tropism to the lung, which
is why it was selected for this aim. The AAV9 contains a guide RNA (gRNA) targeted to the
Rosa26 mouse locus, and delivers the barcode sequence and GFP between Rosa26 homology
arms (Figure 6A). The gRNA will guide Cas9 to the Rosa26 locus, where Cas9 will make a
double-stranded DNA cut. As the cell works to repair the cut, the Rosa26 homology arms
supplied by the AAV9 will be used in the homology directed repair, and the GFP-Barcode
cassette will be inserted in to the genome as the repair is complete. As indicated in the methods,
prior to being made in to virus, a number of colonies were screened to ensure unique barcodes in
a few colonies. The plasmid was sent to the University of Michigan Viral Vector Core to be
made in to AAV9.
3.2: Profiling of the barcoding AAV
To understand the diversity in barcodes, I used next-generation targeted amplicon sequencing of
just the barcode region. In order to avoid introducing errors in the PCR steps of the library
preparation for the amplicon sequencing, I worked to amplify the barcode insert with the lowest
number of PCR cycles possible (Figure 6B). The barcodes from the plasmid pool and the AAV9
pool were sequenced via targeted amplicon sequencing at Genewiz. To ensure the most accurate
representation of the true number of barcodes in the population, the number of PCR cycles
determined in Figure 7B, along with an estimation of PCR error based on the error rate in the
constant regions of the barcode was used to group together barcodes that may have seemed
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unique but were actually a result of PCR error. By using the PCR backtracking, combined with
Chao2 modeling of diversity using the plasmid pool and viral pool as two unique samples, an
overall diversity of around 1,300 barcodes was determined (Figure 6C).
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Figure 6: Validation of the AAV9 barcoding construct
A: The construct contains homology arms to the Rosa26 locus flanking a GFP, the barcode
sequence (inset), and a polyA sequence. This will insert the entire GFP barcoding cassette during
HDR after Cas9-directed cutting at Rosa26. The plasmid also contains a gRNA directed to
Rosa26 to guide the Cas9 to the appropriate site to make the cut. B: Determination of the optimal
number of PCR cycles prior to targeted amplicon sequencing. The barcode sequence was
amplified from the AAV plasmid, and a small amount of sample was removed at each PCR cycle
and run on an agarose gel to determine the cycle number at which a band corresponding to the
size of the barcode amplicon appears. As indicated by the arrows, a band corresponding to the size
of the barcode begins to appear at 29 PCR cycles, and DNA sufficient for sequencing is able to be
extracted. C: Diversity of the barcoding vector was determined with miSeq and Chao2 modeling.
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3.3: Generation and validation of the TKO-Cas9 mouse model
Our SCLC mouse model is driven by Cre-based deletion of the tumor suppressors Rb, p53, and
p130 (RPR model). The RPR mouse model has been used many times and is a reliable model of
SCLC11,61. I bred it with an H11lox-stop-lox-Cas9 mouse to generate the RPR-Cas9 (Rblox/lox, p53lox/lox,
p130lox/lox, H11lox-stop-lox-Cas9) model. The mice rapidly develop tumors after intratracheal injection
with an Ad-CMV-Cre adenovirus. To determine the optimal concentration of adenovirus, I
injected mice with varying concentrations of the Ad-CMV-Cre virus and stained their lungs with
antibodies against both Cre (to determine viral uptake) and Cas9 (to determine functional output
of Cre recombination). Antibodies against Cas9 were not very good, so I used Cre
immunostaining as the threshold by which to select the concentration of Ad-CMV-Cre (Figure
7).
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Figure 7: Lung histology to titer the Ad-CMV-Cre virus
Varying concentrations of Ad-CMV-Cre were injected intratracheally in to mouse lungs, and
histology was performed to to evaluate staining for Cre (left), and the functional output Cas9
(right). 10 ul of virus is sufficient to initiate expression of Cas9 in the lungs.
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Tumors generally start from a single cell and clonal diversity then develops over the course of
the tumor growth. If tumors are barcoded too early, they could be barcoded at the single cell
stage, and clonal diversity would be lost, as all cells within the tumor will share the same
barcode. Conversely, if tumors are barcoded too late, the heterogeneity will have already formed,
and clonal dynamics will not be able to be understood, as clones likely sharing the same lineage
will receive different barcodes. Since the ideal timing for barcoding is unknown, I designed a
matrix system for barcoding and analysis of tumors (Figure 8A). This matrix will allow us to
barcode and analyze tumors from early tumor formation stages through endpoint-stage disease.
By barcoding and harvesting tumors in the matrix schedule, all combinations of barcoding and
harvesting are captured and I will capture the ideal timeline for tumor heterogeneity.
To validate the barcoding AAV9-r26-GFP-BC virus, mice were given Ad-CMV-Cre, followed
by AAV9-r26-GFP-BC two days later, and were euthanized after another two days. Lungs were
stained for GFP. After tumor initiation and barcoding, mice were allowed to progress to their
scheduled endpoint, or until moribund, whichever came first. Two mice were given
chemotherapy at five months post-tumor initiation, and these mice were allowed to progress to
moribund (Figure 8A). All RPR-Cas9 mice that were euthanized at five months have extensive
tumor burden, so this timepoint was selected for chemotherapy treatment initiation to mimic the
general clinical progression, as the majority of patients present with extensive-stage disease. At
their endpoint, lungs and livers were harvested from all mice, and flow cytometry was performed
to isolate the GFP+ barcoded tumor cells before scRNA-seq (Figure 8B, C, D).
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Figure 8: Validation of barcoded tumors
A: Timeline for tumor barcoding and isolation. Tumors were barcoded at one month intervals
following tumor initiation, and tissues were harvested at one month intervals following barcoding. A
subset of the mice received chemotherapy. B: Example FACS plots from a lung and liver sorted for
GFP+ barcoded tumor cells. C: Example histology showing cells stained with an antibody against
GFP in four tumors barcoded and harvested at various times. D: Repressive images of a lobe of the
lung showing GFP+ tumor lesions under a dissecting microscope.
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Chapter 4: Single-cell RNA Sequencing of SCLC Tumors Barcoded
in situ Identifies Genetic Signatures for Tumorigenesis
4.1: Two distinct transcriptomic signatures arise during tumorigenesis
After tumors were harvested, flow cytometry was performed to isolate GFP+ cells, and they were
used for scRNA-seq. Data was trimmed and aligned to the mouse genome using CellRanger. The
resulting data was then used in Seurat to filter out low-quality cells, attempt to extract barcode
data, and correct for cell cycle genes. Clustering was performed in Seurat to identify unique
cellular populations.The scRNA-seq analysis is shown in Figures 9-14.
Upon analysis of the scRNA-seq data, no barcodes were detectable in the tumors barcoded in
situ. Despite having tumors that are immuno-reactive to antibodies against GFP (Figure 8C), and
the detection of GFP+ cells via flow cytometry (Figure 8D), the depth of scRNA-seq in this case
was not sufficient to pick up reads from the GFP and barcode. Although barcodes were not
detected in these samples, due to the timewise design of the animal studies, information on tumor
evolution can still be gained. We observe the majority of cells sequenced are indeed SCLC cells,
characterized by classic SCLC neuroendocrine markers. Other cell types that can be identified
are myeloid, club, alveolar, ciliated cells, and T and B immune cells (Figure 15B). When
evaluating the cell cycle composition of the cells within the tumor populations, the proportion of
cells in G1 decreases with each subsequent month that tumors are allowed to form, and the
percentage of cells in G2 or metaphase increases significantly after five months of tumor
development (Figure 15C) We observe an “early” tumor signature that arises in the tumors
isolated after two months of development, and a population of cells maintains the early signature
through later tumor development, up to 5.5 months after tumor initiation. In the later months of
tumor development, a “late” signature emerges, which eventually is responsible for the majority
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of the tumor in the longest developed tumors (Figure 15D, E). The gene signatures that
characterize the early and late tumor populations differ at several gene “modules” but
particularly module five (Figure 15F). Module five is notably comprised of the known SCLC
regulators Myc and Hes, and also members of the AP-1 network.
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Figure 9: Pre-trimming scRNA-seq, in situ
A: Number of genes detected per sample, for all samples including lung (Lu), liver (Li) and lymph
node (Ly). B: Percentage of reads corresponding to mitochondrial genes in all in situ samples. C:
Percentage of reads corresponding to ribosomal genes. D: Correlation between percent
mitochondrial reads and number of genes (left), or number of genes and number of features (right).
Cells with a high percentage mitochondrial genes and low number of genes were filtered out as dead
cells. Using the features vs reads plot, doublets were filtered.
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Figure 10: Post-trimming scRNA-seq, in situ
A: Number of genes sequenced per cell after trimming. B: Number of genes sequenced per cell
after sequencing for only the lung samples. C: Number of genes sequenced by cell stratified by
whether or not the animal received chemotherapy treatment. “No” indicates no chemotherapy
treatment, and “yes” indicates chemotherapy treatment. D: Number of genes sequenced per cell
stratified by the month of tumor harvest. The early timepoints (months 2 and 3) are lower in reads
than the later timepoints. E: Post-trimming percentage of reads that correspond to mitochondrial
genes.
42

Figure 11: Cell cycle correction, in situ
A: Cell cycle marker genes pre-set by Seurat show the distribution of cells corresponding to each
stage of the cell cycle. B: Amount of KI-67 expressed in each sample, indicating these cells are
cycling. C: UMAP showing the distribution of lung samples (left), and the cells that are in each phase
of the cell cycle (right). D: Cell cycle state plotted by principal component. Left – PC plot showing
the distribution of the lung samples. Right – PC plot indicating which cells are in each phase of the
cell cycle.
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Figure 12: Stratification of cells based on two principal components, in situ
A: Top ten genes identified with Seurat analysis. B: DEG identified by PC-1 (left) and PC-2 (left).
Top differentiated genes include Ascl1, Egr1, and members of the AP-1 network. C: Distribution of
cells when split on two principal components.
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Figure 13: Increasing dimensionality leads to decreased standard deviation
A: Heatmaps of increasing dimensions. B: Elbow plot indicating the decrease of standard deviation
with each increased dimension.
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Figure 14: UMAP and clustering to generate a pseudotime trajectory, in situ samples
A: Left – UMAP of all lung samples. Left – clustering used for downstream analysis. B: UMAP with
the distribution of cells color-coded with the time of tumor harvest in months. C: Pseudotime
trajectory showing multiple, divergent routes of tumor evolution.
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Figure 15: Single cell RNA sequencing of in situ tumors reveals two distinct tumor populations
A: Schematic overview of the in situ barcoding approach. Tumors are initiated with Ad-CMV-Cre,
and are barcoded with the AAV9-R26-GFP-BC virus at one month intervals post-initiation. At onemonth intervals following barcoding, tumors were harvested and underwent scRNA-seq. B: scRNAseq detected many cell types in the lung, including SCLC tumor cells. C: At each month post-tumor
initiation, the proportion of cells in G1 significantly decreases and the proportion of cells in G2/M
significantly increases. D: Tumor cells stratify in to two populations – “early” and “late” (left). The
early population is predominant in the tumors collected at two and three months post-initiation, while
the late population arises in the tumors harvested later. E: Proportion of cells at each tumor harvest
timepoint that correspond to the early or late clusters. Over time, the majority of the tumor is
comprised of the late population. F: Gene modules differentiate the early and late tumor clusters.
Eight gene modules can describe the transcriptomic differences between the early and late tumor
clusters. Particularly of note is module 4, which contains Myc and Hes, as well as members of the AP1 network.
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4.2: The role of the AP-1 network in mediating tumorigenesis
The AP-1 network was frequently identified in the scRNA-seq data from early, middle, and late
tumors, and cells high in the AP-1 network signatures were frequently found in both the “early”
and “late” tumor clusters, but at particularly high levels in the late cluster (Figure 16A, B). The
AP-1 network has been found to be responsible for a number of tumor hallmarks including
growth, resistance to therapy, and angiogenesis, and expression has been implicated in many
tumor types65-76. Given the strong links to tumorigenesis in other cancer types, I sought to
understand the implications of AP-1 network activation in SCLC. cJun is one of the most
common components of the AP-1 network, and the majority of network functions can be
inhibited via knockdown of cJun using a dominant-negative Jun construct (JUNDN)64,65,68. Jun
was found to be highly expressed in this study, particularly in the late tumor cluster (Figure
16B). I transfected the four SCLC lines (H29, H82, H209, H1836) with the JUNDN construct
pMIEG3-JunDN, and did FACS to isolate the GFP+ cells that had been successfully transfected.
Due to poor expression in the H209 and H1836 cell lines, only the H29 and H82 cell lines were
successfully transduced and will be used for downstream crystal violet analysis.
The resulting cells were used for a soft agar colony forming assay to assess the capability of cells
with disruption of AP-1 to form colonies from a single cell suspension. JunDN cells formed
significantly fewer colonies than wild-type cells did (Figure 16C, D). Disruption of the AP-1
complex by knockdown of cJun inhibits colony formation, indicating that the AP-1 complex is
important in tumor formation in SCLC. Validating these results in SCLC-A cell lines, which are
notoriously difficult to transfect, would be a beneficial route of follow-up. The cells from the
tumors treated with chemotherapy cluster predominately with the late cell cluster and are high in
AP-1 network signatures (Figure 16E).
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Figure 16: The AP-1 network is required for tumorigenesis.
A: Relative expression of genes belonging to the AP-1 network that are highly expressed in both the
early and late tumor clusters, but to a higher degree in the late tumor cluster. B: UMAPs showing
expression of Fos (left) and Jun (right), two critical members of the AP-1 complex. The expression of
Fos and Jun is high in the sequenced tumor cells, and is particularly high in the cluster corresponding
to the late population. C: Representative images of crystal violet staining after AP-1 inhibition due to
Jun knockdown in SCLC cell lines that were used for a soft agar colony forming assay. The cells with
AP-1 disruption formed significantly fewer colonies than the wild-type cells. D: Quantification of the
soft agar colony forming assay shows significantly fewer colonies in the AP-1 disrupted cells. E:
UMAP of all sequenced tumor cells, including those that received chemotherapy. The majority of the
cells from the chemotherapy treated tumors cluster with the late tumor cluster.
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Chapter 5: Generation and Validation of Barcoded SCLC
Xenografts
5.1: Synthesis and profiling of the barcoding retrovirus
The retrovirus barcoding construct was designed to contain a CAG promoter to ensure
expression regardless of the site of viral insertion, followed by a GFP, the barcode sequence, and
finally a polyA sequence to give the highest chance of sequencing the barcode with the 10X
Genomics 3’ capture technology (Figure 17A). After cloning, the rGFP-BC plasmid was profiled
for diversity of barcodes using targeted amplicon sequencing. To avoid erroneously introducing
errors in the barcodes, the minimal number of PCR cycles needed to amplify the barcode was
determined by removing a portion of the sample after each PCR cycle and running a gel to
screen for the lowest number of cycles required to get a band that produces sufficient quantity of
DNA for sequencing (Figure 17B). After determining the optimal number of PCR cycles, the
plasmid pool and viral pool were sequenced to determine barcode diversity via targeted amplicon
sequencing. After targeted amplicon sequencing, the same PCR error rate correction and Chao2
modeling was performed as with the AAV barcoding vector, and the estimated diversity of
barcodes is roughly 6,000 unique barcodes (Figure 17C).
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Figure 17: Generation and validation of the barcoding retrovirus
A: The retroviral barcoding constructs contains a CAG promoter, GFP, and the barcode sequence with
a 3’ polyA tail. B: Determination of the optimal number of PCR cycles to amplify the barcode
sequence for targeted amplicon sequencing. The barcode sequence was amplified via PCR, and a
subset of the sample was removed each cycle and run on a gel to identify at which PCR cycle a band
corresponding to size of the barcode amplicon would appear. As indicated by red arrows, a band is
faintly visible at 11 PCR cycles, and 16 PCR cycles is sufficient to obtain DNA for sequencing. C:
Diversity of the barcoding retrovirus was determined via miSeq and Chao2 modeling, and was
determined to be around 6000 unique barcodes.
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5.2: Profiling of barcode diversity across doubling times in cells
Before generating xenografts, a subset of the cells are collected to serve as a “pre-injection”
sample, however, since each cell should receive a unique barcode, I want to ensure that the
barcodes captured in the “pre-injection” sample match the barcodes that are in the xenografted
cells, so that they are able to be traced back to their starting population using the barcode
sequence. In order to ensure the barcodes captured in the pre-injection sample and the xenograft
have sufficient overlap, I set up a doubling time experiment, in which cells would be barcoded,
and at each doubling, the cells harvested and split in two. The barcodes of the two independent
samples are then be profiled with targeted amplicon sequencing, and the overlap in barcodes in
the two halves of the same initial sample quantified. In this experiment, the two halves of the
initial barcoded cell pool represent the pre-injected sample and the injected xenograft. By
assessing the barcode overlap over four doublings, the optimal number of doublings for
sufficient overlap will be identified. For the four SCLC lines, H29, H82, H209, and H1836, the
normal doubling time is not known, so I seeded a known number of cells and every 24 hours
counted the number of cells in the sample to calculate the doubling time for these four lines
(Figure 18A). Since only the H82 (SCLC-N) and H209 (SCLC-A) cell lines are being used to
make xenografts, these are the lines that were used for the barcode overlap experiment. Cells
were barcoded in culture and at each doubling, as determined in Figure 19A, one well was
harvested, split in half (Figure 18B). After harvesting and splitting the cells, the RNA was
extracted and the barcodes were amplified using the minimal number of PCR cycles to amplify
just the barcode region, as in Figure 18B, and the barcode region was sequenced with Illumina
miSeq (Figure 18C). An R script was generated to determine the percent overlap in barcodes and
to model the percent overlap if the experiment was repeated 1000 times (Figure 18D). As
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determined by both the sequencing and the modeling, the percent overlap between two halves
starts relitivley high at about 60% and increases over time before plateauing. Additionally,
because one cell population will be used to make four xenografts, an R script was used to
determine the percent overlap in barcodes if one sample was split in half (pre-injection sample),
and the other half was split in to four (four xenografts). The overlap between two individual
xenografts (Figure 18E) and the overlap between the pre-injection sample and individual
xenografts (Figure 18F) was determined. From the sequencing and modeling of the barcode
overlap, three doublings appears to be the most optimal to maximize barcode overlap between
the pre-injection sample and the xenografts, and to minimize the barcode overlap between
xenografts, so that they may serve as biological replicates. To further assure that three doublings
is sufficient to observe overlap, I validated the simulated experiment by performing it using
SCLC cells in culture. Cells were barcoded in culture and after three doublings, 15,500 cells
were used as the “pre-injection sample” and four samples of 2,500 cells each served as a
xenograft, since 15,500 cells will be sequenced pre-injection and 2,500 cells are used to make
each xenograft (Figure 18B). Based on the overlap in barcodes observed in the targeted amplicon
sequencing, it is clear that three doublings is sufficient to achieve overlap in barcodes between
the pre-injection sample and injected xenografts (Figure 18G).
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Figure 18: Sequencing and modeling of barcodes in cells infected with the barcoding
retrovirus.
A: Doubling time of two SCLC cell lines, H82 (SCLC-N) and H209 (SCLC-A). Cells were seeded
at a known concentration and counted daily. The doubling time is determined as 2-3 days. B:
Schematic of the doubling time experiment. Cells in culture are barcoded and at each doubling, a
well is harvested, split in half, and barcodes sequenced. If one of the halves is split in to four
independent samples, they are indicated as subsamples. C: Overlap in barcode sequences in two
halves at each doubling. D: Modeled overlap in the barcode sequences over doubling times. The
modeling was simulated 1,000 times. E: Modeled overlap between two subsamples over five
doublings. F: Modeled overlap between one subsample and the remaining half of the well. G:
Overlap in barcodes at three doublings in the amount of cells actually used for xenografting
(“subsample”) and pre-injection scRNA-seq (“half”).
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5.3: Generation of xenografts and chemoresistant xenografts
After validating and profiling the barcodes, xenografts were generated by barcoding H209
(SCLC-A) or H82 (SCLC-N) cells in culture, allowing them to double three times, and injecting
2,500 cells per xenograft in 1:1 matrigel in to the hind flank of immunocompromised mice. After
palpable, the tumors were measured daily (Figure 19A, B). As expected, the SCLC-N H82
xenografts (Figure 19B) grew much more rapidly than the SCLC-A H209 xenografts (Figure
19A). Clinically, patients that have SCLC-N tumors do more poorly, and SCLC-N subtype is
most often associated with chemoresistance, so more aggressive growth behavior from the
SCLC-N xenografts is logical. After the chemo-naïve tumors had reached their endpoint, they
were dissected and 15,500 cells were used for scRNA-seq, while the rest were injected in to the
hind flank of a new mouse as a serial xenograft, which received cisplatin and etoposide. Again,
the SCLC-N xenografts grew more aggressively under chemotherapeutic pressure than the
SCLC-A xenografts (Figure 19C). There was a response to chemotherapy in a subset of the
SCLC-A xenografts, but all tumors ultimately regrew as chemoresistant tumors. All
chemoresistant tumors were dissected and subject to scRNA-seq. Upon dissection the tumors are
GFP+ under a fluorescent dissecting microscope, indicating that they are indeed barcoded, since
the barcode is fused to a GFP (Figure 19D).
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Figure 19: Generation and growth of barcoded and chemoresistant xenografts.
A: Four xenografts were generated from barcoded SCLC-A cells and were allowed to grow until the
size threshold was reached. B: Growth curves from the four barcoded SCLC-N Xenografts.
Xenografts were generated and allowed to grow until the size threshold. C: Xenograft growth under
chemotherapy. Barcoded xenografts were serially injected in to new mice, which received three
weeks of chemotherapy treatment. SCLC-A tumors (top) were somewhat responsive to
chemotherapy, but eventually re-grew. SCLC-N tumors (bottom) were generally resistant to
chemotherapy. D: Images of dissected barcoded tumors. Tumors displaying visible GFP expression
were dissected, indicating some degree of barcoding in these samples.
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Chapter 6: scRNA-seq of Barcoded Xenografts Reveals Increased
Transcriptomic Plasticity in SCLC-A Tumors
6.1: SCLC-A tumors exhibit transcriptomic changes after chemoresistance
All xenografts, as well as the pre-injection sample underwent scRNA-seq to profile their
transcriptomes on a single cell scale. scRNA-seq data was trimmed, QC performed, and mapping
to the genome was performed via CellRanger. Given that the xenografts were not flow-sorted,
there may have been contaminating mouse cells in the data. A mapping statistic was assigned to
each cell, and it was determined that very few of the cells belong to the mouse genome (Figure
21D, Figure 27D). These cells were excluded from the resulting analysis. The data was then used
in Seurat, where cells with poor quality reads were filtered out, the barcoding data was extracted,
and cell cycle correction was performed. Loupe was used to visualize the final, processed data.
Data analysis is shown in Figures 20-35.
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Figure 20: SCLC-A scRNA-seq samples before trimming
A: Overview of the lineages that exist in these samples. B: Number of genes detected per sample.
Sample R_1420_P has very few genes detected and is of low quality, and should be filtered out. C:
Percentage of reads corresponding to mitochondrial genes. D: Percentage of reads corresponding to
ribosomal genes. E: Correlation between percent mitochondrial reads and number of genes (left).
Cells with a high percentage mitochondrial genes and low total number of genes were filtered out as
dead cells. Correlation between number of features and number of genes detected (right). Doublets are
filtered out.
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Figure 21: SCLC-A post-trimming scRNA-seq.
A: Number of genes sequenced per cell after trimming the dead cells and doublets. B:
Percentage of reads corresponding to mitochondrial genes. C: Percentage of reads
belonging to ribosomal genes. D: Number of cells that match either the mouse or human
genome. The xenografts are human cells, but were injected in to mice, so it is possible that
a few of the cells that were sequenced were stromal mouse cells. Very few of the reads
correspond to the mouse genome, but some were still captured. E: Post-trimming
correlation of percentage of mitochondrial reads and number of sequenced genes (left) and
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correlation of number of features and number of genes (right).

Figure 22: Cell cycle analysis of the SCLC-A scRNA-seq samples
A: Cell cycle marker genes pre-set by Seurat show the distribution of cells corresponding to each
stage of the cell cycle. B: Amount of KI-67 expressed in each sample, indicating these cells are
cycling, with the degree dependent on the sample. C: UMAP showing the distribution of the SCLC-A
samples (left), and the cells that are in each phase of the cell cycle (right). D: Top 10 genes as
determined by Seurat. This analysis averages all samples.
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Figure 23: Stratification of the SCLC-A samples based on two principal components
A: DEG identified by PC-1 (left) and PC-2 (left). B: Distribution of cells when split on two principal
components.
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Figure 24: Increasing dimensionality leads to decreased standard deviations in the SCLC-A
samples
A: Heatmaps of increasing dimensions. B: Elbow plot indicating the decrease of standard deviation
with each increased dimension.
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Figure 25: UMAP and clustering used to generate a pseudotime trajectory of the SCLC-A
samples
A: Left – UMAP of all SCLC-A samples. Left – clustering used for downstream analysis. B: Seurat
analysis automatically clustered the cells in to two clusters, blue (no chemotherapy) and red
(chemoresistant cells). C: Trajectory analysis based on the clustering from B. D: Pseudotime
trajectory using the clustering from A and accounting for the time-based resolution. The lineage starts
in the cell line and continues through the chemo-naïve cells, in to the chemoresistant ones.
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Figure 26: SCLC-N scRNA-seq results before trimming
A: Overview of the lineages that exist in these samples. B: Number of genes detected per sample. C:
Percentage of reads corresponding to mitochondrial genes. D: Percentage of reads corresponding to
ribosomal genes. E: Correlation between percent mitochondrial reads and number of genes (left).
Cells with a high percentage mitochondrial genes and low total number of genes were filtered out as
dead cells. Correlation between number of features and number of genes detected (right). Doublets are
filtered out.
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Figure 27: scRNA-seq data post-trimming for the SCLC-N samples
A: Number of genes sequenced per cell after trimming the dead cells and doublets. B: Percentage of
reads corresponding to mitochondrial genes. C: Percentage of reads belonging to ribosomal genes. D:
Number of cells that match either the mouse or human genome. The xenografts are human cells, but
were injected in to mice, so it is possible that a few of the cells that were sequenced were stromal
mouse cells. The vast majority of cells corresponded to the human genome, but a few mouse cells
were captured. E: Post-trimming correlation of percentage of mitochondrial reads and number of
sequenced genes (left) and correlation of number of features and number of genes (right).
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Figure 28: Cell cycle analysis of the SCLC-N scRNA-seq analysis
A: Cell cycle marker genes pre-set by Seurat show the distribution of cells corresponding to each
stage of the cell cycle. B: Amount of KI-67 expressed in each sample, indicating these cells are
cycling. C: UMAP showing the distribution of the SCLC-N samples (left), and the cells that are in
each phase of the cell cycle (right). D: Top 10 genes as determined by Seurat. This analysis averages
all samples.
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Figure 29: Stratification of the SCLC-N xenograft samples based on two principal components
A: DEG identified by PC-1 (left) and PC-2 (left). B: Distribution of cells when split on two principal
components.
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Figure 30: Increasing dimensionality leads to decreased standard deviations in the SCLC-N
samples
A: Heatmaps of increasing dimensions. B: Elbow plot indicating the decrease of standard deviation
with each increased dimension.
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Figure 31: SCLC-N samples UMAP and clustering to generate a pseudotime trajectory.
A: Left – UMAP of all SCLC-N samples. Left – clustering used for downstream analysis. B:
Pseudotime trajectory accounting for a time-based resolution. Left – clustering used to generate the
pseudotime trajectory. Right – SCLC-N pseudotime projection. The lineage is very branched, with
two main projections arising from the initial cellular population and diversifying as the xenografts
grow and acquire enhanced chemoresistance.
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Figure 32: All xenograft scRNA-seq combined together, post-trimming.
A: Number of genes sequenced per cell for both the SCLC-A and SCLC-N cohorts. B: Percentage of
reads corresponding to mitochondrial genes. C: Due to some tumors being collected at different
timepoints, there is a batch effect that must be accounted for. C shows the UMAP for all samples prior
to batch correction. H209 – SCLC-A cell line, H209X – SCLC-A xenograft, H209XCR – SCLC-A
xenograft treated with chemotherapy, H82 – SCLC-N cell line, H82X – SCLC-N xenograft, H82
XCR – SCLC-N xenograft treated with chemotherapy. D: All xenograft samples UMAP after batch
correction. E: Top 10 genes expressed as determined by Seurat.

70

Figure 33: Distribution of all xenograft samples based on two principal components
A: Top differentially expressed genes from one (left) or two (right) principal components. B:
Distribution of cells when two principal components are used.
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Figure 34: Increasing the number of principal components in all xenograft samples decreases
standard deviation and variance.
A: Heatmaps showing DEGs when the data is stratified with increasing components. B: Elbow plot
demonstrating the relationship between standard deviation and number of principal components. C:
Variance in the data explained fully by components decreases with each additional component added.
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Figure 35: Clustering of all xenograft samples reveals similarities between chemoresistant
SCLC-A tumors and SCLC-N tumors
A: UMAP of all xenograft samples coded by their sample type. H209 – SCLC-A cell line, H209X –
SCLC-A xenograft, H209XCR – SCLC-A xenograft with chemotherapy, H82 – SCLC-N cell line,
H82X – SCLC-N xenograft, H82XCR – SCLC-N xenograft treated with chemotherapy. B: UMAP of
all xenograft samples color coded based on their sample number. C: Clustering used for lineage
trajectory set by Seurat. D: Lineage trajectory of all SCLC-A and SCLC-N tumors. E: Pseudotime
reconstruction for all SCLC-A and SCLC-N tumors combined.
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There is a large transcriptomic shift between chemo-naïve tumors and chemotherapy treated
tumors in SCLC-A xenografts (Figure 37A). In contrast, the SCLC-N tumors do not display a
large shift after chemotherapy (Figure 37A). It is known that SCLC-N tumors can be more
chemoresistant, so it makes sense that there would not be much of a transcriptomic difference
between tumors treated with chemotherapy and tumors without. In contrast, SCLC-A tumors are
often chemo-sensitive and a shift in gene expression is seen after chemoresistance is acquired.
This is what has been observed here. The tumors that start as SCLC-A take on more of the
NEUDOD1-high SCLC-N profile after chemotherapy (Figure 37B). In the SCLC-A pre-injection
sample, the transcriptomes of these cells cluster mostly separately from the tumors they form,
indicating either a bottleneck event, or transcriptomic shift during the event of tumor formation
(Figure 36B). By utilizing the barcodes, we are able to match transcriptomes to lineage barcodes
and are able to ascertain which phenomenon occurred. There are however a few cells that belong
to the pre-injection sample that cluster more closely with the formed tumors. These could
potentially be the tumor initiating cells that survived the bottleneck event to form the eventual
tumor. Similarly, there are a handful of cells from the chemo-naïve tumors that cluster more
closely with the chemoresistant tumors in the SCLC-A xenografts (Figure 36D). These could
potentially be cells that are inherently chemoresistant that have the ability to give rise to a
chemoresistant tumor after selection by chemotherapy. With the barcodes, we are able to track
the chemoresistant cells back to the initial tumor populations to make that determination. The
SCLC-N xenografts display a much lower degree of transcriptomic shift between the preinjection sample, the chemo-naïve xenografts, and the chemoresistant xenografts (Figure 36A, C,
F). Due to the known propensity for SCLC-N tumors to be chemoresistant, it is understandable
that little to no transcriptomic shift after chemoresistance would occur. Still, these cells are
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barcoded, and we have the ability to identify the populations of cells that were able to form
tumors and re-grow the tumors after chemotherapy treatment.
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Figure 36: Transcriptomic plasticity is observed in SCLC xenografts.
A: UMAP of the SCLC-N xenograft samples. There is no striking difference in the chemotherapy
treated and chemo-naïve populations. B: UMAP of all the SCLC-A samples. A robust transcriptomic
shift is observed post-chemotherapy. C: UMAP of only the SCLC-N samples that did not get
chemotherapy, and the pre-injection sample. D: UMAP of the SCLC-A samples with the samples that
received chemotherapy removed. A few cells that correspond to the chemo-naïve cells cluster where
the chemoresistant cells do. These could potentially be the cells with inherent chemoresistance that
are responsible for seeding the chemoresistant tumor after chemotherapy. E Heat map showing top
DEG in the SCLC-A samples. The transcriptomic difference between the chemo-naïve and
chemoresistant samples is apparent. F: Heatmap of the top DEG for the SCLC-N xenografts. Much
more transcriptomic homogeneity is observed in these samples.
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Figure 37: Expression of SCLC subtype genes show a conversion from SCLC-A to SCLC-N in
chemotherapy treated tumors.
A: UMAPs of the SCLC-N (left) and SCLC-A (right) tumors color-coded by sample. The SCLC-N
tumors do not show a transcriptional shift after chemoresistance, while the SCLC-A tumors
demonstrate robust transcriptional changes, indicated by the leftward shift in the chemoresistant
samples. B: UMAPs highlighting expression of SCLC subtype genes ASCL1 and NEUROD1 in
SCLC-N (left) and SCLC-A (right) tumors. The SCLC-N tumors are low in ASCL1 and high in
NEUROD1 regardless of treatment status, while the SCLC-A tumors shift from ASCL1 high to
NEUROD1 high after chemotherapy. This corresponds with a shift from MYCL expression to MYC
expression, which has been previously documented as part of this subtype switch.
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Chapter 7: Cancer Testis Antigens are Mediators of
Chemoresistance in SCLC
7.1: Cancer Testis Antigens PAGE5 and GAGE2A are expressed in chemoresistant
populations
Cancer/Testis Antigens (CTA) are a large class of proteins almost exclusively expressed in the
male germ cells and tumors. CTAs have shown promise as potentially targetable, unique cancer
antigens. For this reason, they make excellent candidates for immunotherapy such as CAR-T
therapy and cancer vaccines77-83. In addition to their role as potential cancer antigens, CT
antigens also have oncogenic effects on proliferation, genomic stability, invasion, colony
formation, and resistance to apoptosis78,79,81. In the scRNAseq, CTAs were significantly
upregulated (Figure 38A, B). In particular, PAGE5 and GAGE2A were significantly upregulated
after chemotherapy in SCLC-A xenografts. In the inherently chemoresistant SCLC-N xenografts,
PAGE5 and GAGE2A were highly expressed in all populations. PAGE5 has been identified to
be expressed in some cancers, and in melanoma was elevated as an anti-apoptotic gene in
response to platinum-based chemotherapy. Expression of PAGE5 was shown to be pro-survival,
and upregulated genes related to melanoma cell survival84. GAGE2A is another anti-apoptotic
CT antigen, that seems to be related to treatment resistance in medulloblastoma85. I therefore
sought to investigate the role of PAGE5 and GAGE2A in mediating chemoresistance in SCLC.
To evaluate the effect of chemotherapy treatment on expression of PAGE5 and GAGE2A, H29,
H82, H209, and H1836 SCLC cell lines were treated with chemotherapy in culture. The IC50
value for cisplatin and etoposide treatment of cells was first determined by treating H82 or H209
cells with varying concentrations of cisplatin or etoposide, and proliferation was assessed via
alamar blue assay (Figure 39A). The resulting IC50 concentration was used for the remainder of

78

the in vitro chemotherapy response experiments. All four cell lines were treated with the IC50
dose of cisplatin or etoposide, and two or three days later, cells were harvested for RNA and
expression of PAGE5 or GAGE2A was assessed with qPCR. Cells treated with cisplatin or
etoposide demonstrate higher expression of PAGE5 and GAGE2A than cells not treated with
chemotherapy (Figure 38C), indicating cells increase the expression of CTAs in response to
chemotherapy treatment in culture. In order to understand how chemotherapy treatment impacts
CTA expression, xenografts using the four SCLC lines were generated in NSG mice. After
tumors were palpable, some mice were treated with chemotherapy. When the mice had reached
their endpoint, tumors were dissected and stained for expression of PAGE5 and GAGE2A.
Tumors generated from SCLC-N cell lines (H29 and H82) stained positively for expression of
PAGE5 and GAGE2A (Figure 38D). Tumors from mice that received SCLC-A tumors (H209
and H1836 cell lines had almost no expression of PAGE5 or GAGE2A until after chemotherapy
treatment (Figure 38D). SCLC-A cells express CTAs at a very low level prior to chemotherapy
treatment, while SCLC-N cells and tumors express CTAs at a moderate level, which is increased
upon treatment with chemotherapy. Universally, chemotherapy treatment of SCLC cells in
culture leads to an upregulation of PAGE5 and GAGE2A expression, and treatment of
xenografts with chemotherapy also increases the expression of PAGE5 and GAGE2A (Figure
38). The association between chemotherapy treatment and CTA expression suggests a role of
CTAs in mediating response to chemotherapy in SCLC.
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Figure 38: Cancer testis antigen expression is increased after chemotherapy in SCLC.
A: UMAP of the SCLC-N xenografts demonstrating robust GAGE2A (top) and PAGE5 (bottom)
expression in all sequenced cells. B: SCLC-A UMAP showing increased GAGE2A (top) and PAGE5
(bottom) expression only after chemotherapy treatment. C: GAGE2A (left) and PAGE5 (right)
expression increase after treatment with chemotherapy in culture. SCLC cell lines were treated with
cisplatin, etoposide, or combination therapy, and the level of GAGE2A or PAGE5 expression was
assessed via qPCR. A marked increase in expression is observed. D: SCLC xenografts treated with
chemotherapy show increased immunostaining of GAGE2A and PAGE5. SCLC-N xenografts (left)
have existing expression of these CTAs, but the SCLC-A xenografts have immunoreactivity only after
chemotherapy treatment.
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7.2: Overexpression of CTAs drives chemoresistance in culture
To investigate the effect of PAGE5 and GAGE2A expression on the response to chemotherapy,
PAGE5 or GAGE2A cDNA was overexpressed via retroviral expression in H29, H82, H209, or
H1836 cell lines (Figure 39B). The cells were treated with the IC50 doses of cisplatin or
etoposide alone or in combination for two days, and cell death was assessed using an Annexin V
and Propidium Iodide flow cytometry assay. Cells with an overexpression of PAGE5 or
GAGE2A were significantly more resistant to cell death caused by cisplatin or etoposide
treatment (Figure 39C). An increase in expression of CTAs in SCLC can confer resistance to
chemotherapy.
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Figure 39: Overexpression of PAGE5 and GAGE2A leads to chemoresistance in SCLC cells in
culture
A: The IC50 value of cisplatin and etoposide was determined via Alamar Blue assay. B: PAGE5 or
GAGE2A were overexpressed via retroviral transduction and the overexpression of PAGE5 (left), or
GAGE2A (center, right) was validated via qPCR. C: Cells with PAGE5 (blue) or GAGE2A (green)
overexpression were treated with chemotherapy in culture and the percentage live cells was assessed
with Annexin V and Propidium Iodide staining. Overexpression of either PAGE5 or GAGE2A lead to
chemoresistance in these cell lines. Paired t-tests were used to determine statistical differences in
percentage live cells between the wild-type and the overexpression groups. N=5 for H29, n=6 for
H82, n=7 for H1836, and n=9 for H209. ns = p>0.05, * = p≤0.05, ** = p≤0.01, *** = p≤0.001, ****
= p≤0.0001.
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7.3: Knockdown of CTAs sensitizes SCLC cells to chemotherapy in culture and xenografts
In order to further investigate the role of CTA expression in mediating chemoresistance, PAGE5
and GAGE2A were knocked down by retroviral expression of shRNAs in four H29, H82, H209,
and H1836 cell lines. To ensure a pure population of cells with PAGE5 or GAGE2A knocked
down, FACS was performed to isolate the populations containing the knockdown construct. The
expression of PAGE5 or GAGE2A was assessed with qPCR (Figure 40A). These single
knockdown cells were treated with cisplatin, etoposide, or combination therapy for two days in
culture and the percentage of dead cells was assessed with Annexin V and Propidium Iodide
flow cytometry assay (Figure 40B). Interestingly, knockdown of PAGE5 or GAGE2A alone was
not sufficient to broadly confer resistance to chemotherapy in culture. Given that both PAGE5
and GAGE2A have been shown to be involved in resistance to cisplatin in the literature84,86, I
investigated the impact of a dual PAGE5 and GAGE2A knockdown on response to cisplatin. I
used the single knockdown shPAGE5 or shGAGE2A SCLC cell lines and added the reciprocal
shGAGE2A or shPAGE5 lentivirus in saturating concentrations. Since both the shPAGE5 and
shGAGE2A lentiviruses use GFP as a reporter, FACS could not be performed after the second
viral infection, so the sorted, pure population received the second virus in a high dose to
maximize the number of cells that get infected with the second virus. After two days in culture,
RNA was harvested and expression of PAGE5 and GAGE2A was assessed via qPCR (Figure
40C). The qPCR data shows that knocking down PAGE5 or GAGE2A reciprocally was
successful and the resulting cell lines had decreased expression of both PAGE5 and GAGE2A.
These double knockdown cell lines were treated with the IC50 dose of cisplatin for two days,
and proportion of dead cells was assessed with the Annexin V and Propidium Iodide flow
cytometry assay (Figure 40D). Cells with both PAGE5 and GAGE2A knocked down were more
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sensitive to cell death caused by cisplatin (Figure 40D). Without cisplatin treatment, there was no
difference in the amount of dead cells in the double knockdown cells, indicating a role of CTAs
in resisting cell death only following treatment with chemotherapy, but the expression of PAGE5
or GAGE2A is not required for cell survival in the absence of chemotherapy. Given that both
PAGE5 and GAGE2A had to be knocked down to sensitize cells to chemotherapy treatment, but
only one had to be overexpressed, the expression of only one of these two CTAs is sufficient to
drive chemoresistance in SCLC cells in culture.
To investigate the impact of PAGE5 and GAGE2A knockdown in vivo, the double knockdown
cell lines were injected as xenografts in to the hind flank of immunocompromised mice. When
tumors were measurable, cisplatin and etoposide were given. The growth of tumors was tracked
over time, and all tumors were collected for histology when they reached euthanasia criteria.
These animal studies are ongoing, as the final growth curves are still being generated.
Preliminarily, animals that received tumors with shGAGE2A and shPAGE5 were much more
responsive to chemotherapy. Some of the mice demonstrated complete response to
chemotherapy, where xenografts were not palpable anymore. This lasted as long as six weeks in
one animal, and there are currently three with complete responses.
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Figure 40: Knockdown of PAGE5 and GAGE2A confer sensitivity to chemotherapy in SCLC
cells in culture.
A: FACS plots during the isolation of GFP+ cells containing the shPAGE5, shGAGE2A, or
shControl constructs. B: qPCR to validate the knockdown of PAGE5 (top) or GAGE2A (bottom).
C: Annexin V and Propidium iodide assay after chemotherapy treatment of the shPAGE5 (blue),
shGAGE2A (green), or shControl (red). Cells that are dead stain positively for both Annexin V and
propidium iodide. In general, a single knockdown of PAGE5 or GAGE2A is not sufficient to confer
chemo-sensitivity. A paired t-test was used to compare the death of the knockdown cells versus the
wild-type cells. N = 7 for all cell types. D: The reciprocal construct was added to the single
knockdown cells and qPCR was used to confirm knockdown of both PAGE and GAGE2A. E:
Annexin V and propidium iodide assay of the double knockdown cells treated with cisplatin show
that knockdown of both PAGE5 and GAGE2A in SCLC-N cells does sensitize cells to death
induced by cisplatin. Unpaired t-tests were used to compare the wild-type to the double knockdown
cells. N = 5 for all double knockdown cells, and n = 7 for all wild-type cells. ns = p>0.05, * =
p≤0.05, ** = p≤0.01, *** = p≤0.001, **** = p≤0.0001.
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7.4: CTAs are signatures of chemoresistance in patient samples
To understand the clinical implications of PAGE5 and GAGE2A expression, I obtained 29
human SCLC biopsies from the Sanford Health BioBank. The tumor sections were stained with
antibodies against PAGE5 or GAGE2A, and slides were scanned with an Apero Slide Scanner.
The samples were quantified based on a binary of any staining, and the overall intensity and
distribution were scored on 0-3 scale. Two additional researchers quantified the staining. The
decision to score by human and not by software was made for a number of reasons. First, many
of the sections had patches of blood, which could be confused by software as being the same
color as the DAB staining. Secondly, given that these are patient biopsies, not all areas of the
tissue are tumor, as areas of surrounding healthy lung are often captured in the biopsy. I wanted
to ensure the scoring only evaluated the tumor areas, and not healthy lung, which is more
straightforward to train a human than a computer on. Additionally, these antibodies produce
variable levels of background staining, depending on tissue processing, which is difficult to
account for via software programs. All researchers that scored tumors were trained in the same
way and were provided a scoring guide with representative images. All scorers also used the
same computer with identical screen settings to further decrease the chance for variability.
Representative images are shown in Figure 41A. The majority of the samples (almost 90%,
Figure 41B) had some positivity towards PAGE5. Around 40% of tumors (Figure 41B)
demonstrated positivity towards GAGE2A. There was some degree of heterogeneity in the
scores of the tumors (Figure 41C), indicating perhaps a role of tumor subtype or treatment status.
We were not able to obtain meta data about patient treatment or response, but pairing that data to
the histology would be an exciting avenue of follow-up.
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Figure 41: Staining and quantification of CTA expression in human SCLC samples
A: Representative images of the human SCLC biopsies stained with antibodies against PAGE5 (left)
or GAGE2A (right). The stain appears as a rust-color DAB staining. B: Fraction of tumor samples
that had any positive staining for PAGE5 or GAGE2A. C: Quantification of the distribution and
intensity of the PAGE5 and GAGE2A staining. Scores range from 0 (no staining) to 3 (very
widespread or strong).
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Chapter 8: Discussion
In this work, I have developed the in situ barcoding model in SCLC. The tumors were
successfully edited, and GFP+ cells were able to be isolated via FACS. Upon analysis of the
scRNA-seq data, no barcodes were detectable. The scRNA-seq sequencing depth was not
sufficient to detect the barcodes via scRNA-seq. Previous work has generally detected barcodes
via DNA sequencing, which is then used to complement the information gained from scRNAseq40,46. Future work in the in situ genetic barcoding field would benefit from insertion of the
barcode at a more highly expressed gene than Rosa26, or by insertion of a strong promoter to
drive expression of the barcode at a rate high enough to be detected with scRNA-seq.
Alternately, an endogenous “barcode” such as the V(D)J region could be used to tag cells, and
the 10X Genomics feature capture technology could be used to readily detect the barcodes.
Despite the absence of the barcode in this model, there are still many insights that can be
gathered from this data. Since tumors were sequenced at one month intervals from early after
tumor initiation until very late stage tumor burden, we are able to evaluate the transcriptomic
makeup of the tumors throughout the course of the disease and reconstruct a lineage hierarchy.
The in situ tumors largely display markers of the ASCL1-high SCLC-A subtype, which is
expected from the RPR mouse model. At the onset of tumor development, the majority of the
tumor cells share a common “early tumor” transcriptomic profile that is higher in stem-like and
neuroendocrine markers. As the tumors progress, the proportion of tumor cells that belong to the
early group decreases, and in its place are cells that belong to a second population of “late
tumor” cells. These are characterized by having less cancer stem cell characteristics and more
highly express members of the AP-1 family. The late tumor population is maintained as the
primary cellular population through the latest tumor time-point. The identification of the early
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tumor population sheds light on the populations responsible for the earliest stages of neoplastic
transformation. The late tumor population identifies the cells that maintain the tumor population
over long periods of time.
One of the most highly expressed networks in the in situ dataset, particularly in the late tumor
cluster, was the AP-1 family. The AP-1 (Activator Protein 1) complex is a powerful
transcriptional controller comprised of members of the FOS, JUN and ATF families (Figure
42A)64. In development and differentiation in iPSCs, it plays a role in chromatin accessibility and
helps to select enhancers to activate cell-specific networks in fibroblast differentiation87,88. It has
been implicated in many tumor types and is responsible for tumor hallmarks like growth,
metastasis, resistance to therapy, angiogenesis, activation of senescence pathways, cell cycle
dysregulation, and inflammation, but the mechanisms by which the AP-1 network impacts tumor
growth are often tumor type specific (Figure 42B)65-76. While the AP-1 network generally acts in
an oncogenic fashion, sometimes family members can act as tumor suppressors. This is
somewhat cell type or cancer type dependent and depends on which Jun protein is expressed
most highly. cJun is most commonly associated with tumor progression and cell cycle
dysregulation, while JunB is generally anti-proliferative, and can even drive expression of tumor
suppressors72, and JunD can act as either oncogenic or suppressive, depending on tumor
type67,73. KRAS driven lung-adenocarcinoma further illustrates the duality of JunD and cJun,
where JunD acts as a pro-tumorigenic factor in response to loss of cJun73. Also in lung
adenocarcinoma, pharmacologic inhibition of AP-1 reduced metastatic formation but not
tumorigenesis of an ex vivo metastasis model89. In lung adenocarcinoma xenografts,
pharmacologic inhibition of an upstream activator of AP-1 signaling reduced both tumor
proliferation and metastasis90. In melanoma, the AP-1 network has a role in the maintenance of
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cellular plasticity and heterogeneity by mediating cell state91,92. AP-1 family members can confer
resistance to both MAPK inhibitors and BRAF inhibitors via activation of c-Jun91,93. Jun family
members have differential roles in melanoma. Knockdown of c-Jun leads to cell cycle arrest and
apoptosis, while knockdown of JunB leads to an increase in proliferation and tumorigenesis, due
to an increase in cJun expression. The combination knockdown leads to apoptosis, indicating that
JunB only acts as a tumor promoter in melanoma when c-Jun is knocked out94. cJun has also
been implicated in liver cancer, where it acts independently of p53 to maintain cell survival in
tumor initiation95. Similarly, in breast cancer, Levels of AP-1 family members were found to be
significantly higher in cancer than in adjacent non-tumor tissues, and patients with high levels of
cJun had a worse outcome96,97. In breast cancer cell culture and xenografts, knockdown of the
AP-1 network by a dominant-negative cJun (DNJun) led to a decrease in proliferation overall
and an inhibition of proliferation in response to growth factors65,98. In this context, the AP-1
network acts as a regulator of the cell cycle by regulating the expression of cyclins and CDKs,
and drives progression by activation of pro-inflammatory cytokines68,97. In Prostate cancer
expression of Fos and JunB are protective against advanced disease, but they are often lost as the
tumor progresses, allowing for the upregulation of cJun, which then drives tumor progression in
late stage99. Despite the links to tumorigenesis and resistance to therapy in other tumors, the role
of the AP-1 network has yet to be evaluated in SCLC.
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Figure 42: AP-1 complex members
A: The AP-1 complex is comprised of members of the FOS, ATF, JUN, or MAF families that
complex together to activate transcriptional networks. Modified from Garces de Los Fayos Alonso et
al., 2018. B: Target genes of the AP-1 complex and their role in cancer hallmarks. A number of gene
targets of AP-1 (“gene product”) are regulated by members of AP-1 (“main regulator”). The target
genes have been found to play a role in a myriad of cancer hallmarks, but these seem to be tumor
type-specific. Modified from Eferl and Wagner, 2003.
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In this work, scRNA-seq identified members of the AP-1 network as playing a role in
tumorigenesis of SCLC. Inhibition of the AP-1 network by transfection with a dominantnegative cJun construct significantly inhibited colony formation of SCLC cells in a clonogeneic
assay. The AP-1 network is required for tumor maintenance in SCLC, and future work should
warrant investigation in vivo of the impact of AP-1 inhibition in SCLC. The bioinformatics
analysis also identified AP-1 as a potential mediator of chemoresistance in SCLC. This is also an
important avenue for future follow-up.
A retroviral barcoding system has been generated to understand tumor dynamics and
heterogeneity over time and under chemotherapeutic pressure in SCLC xenografts. Prior to the
generation of the xenografts, extensive validation of the barcoding system was performed. The
true diversity of barcodes was modeled based on data from targeted amplicon sequencing. The
modeling is a significant advance on current barcoding reports, as estimating the true diversity is
more informative than sequencing alone. Additional validation prior to xenografting revealed
three doublings is optimal to ensure overlap in barcode populations between the pre-injection
sample and the injected xenografts, and three doubling lowers the amount of overlap between
two individual xenografts. Minimal overlap in barcodes between two xenografts is relevant
because they may then serve as biological replicates. If the same population of cells is detected
in two xenografts and they share a barcode, it may be that those cells shared a common lineage
in the cells barcoded in culture and were simply injected in to the xenografts as clones. However,
if the same population of cells is detected in two separate xenografts that have unique barcodes,
there can be some confidence that that lineage arose independently in those two unique
xenografts and it may represent a tumor-relevant biologic phenomenon. Understanding the
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overlap in barcodes by first performing the doubling time experiment led to confidence that the
barcoding system was truly in place prior to xenografting.
Barcoded xenografts were generated and serially injected as barcoded xenografts that received
chemoresistance. All tumors, as well as the initial cellular population were profiled with scRNAseq, and barcodes were detected in all samples, although not in every cell. The reason barcodes
were detectable from the xenografted tumors, but not the in situ barcoded tumors is likely due to
the strong CAG promoter inserted with the GFP and barcode in to the cells used for
xenografting. Additionally, the barcode sequence for the xenografts was inserted by use of a
retrovirus, instead of CRISPR-Cas9. The efficiency of vial insertion is much higher than that of
CRISPR-Cas9, leading to the increased insertion of barcodes in to the cells, and thereby
increasing the likelihood of detecting barcodes by scRNA-seq. After chemotherapy, there is a
broad transcriptomic shift in the SCLC-A xenografts. The SCLC-A barcoded xenografts begin as
tumors that are very high in the expression of ASCL1, the marker for the SCLC-A subtype. As
expected, the SCLC-N xenografts are very high in expression of NEUROD1. As the
chemoresistant tumors develop, the SCLC-A tumors shift from high expression of ASCL1 to
NEUROD1, and the SCLC-N tumors remain consistently high in NEUROD1. SCLC-N tumors
are often more chemoresistant, so the increased expression of NEUROD1 in chemoresistant
tumors is logical. SCLC tumors have been documented to have changes in molecular subtypes,
particularly a shift from SCLC-A to SCLC-N, coinciding with a change in MYC signaling,
which has been documented to play a role in the transition of SCLC subtypes16,18. In these
tumors, a change in MYC signaling was indeed observed in the post-chemotherapeutic shift from
SCLC-A to SCLC-N. Despite the broad transcriptomic shift observed pre-and postchemotherapy in the SCLC-A tumors, there are a handful of cells from the pre-chemotherapy
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tumors that cluster more closely with the chemoresistant tumors. It is not known in SCLC if
chemoresistant is inherent or induced. Inherent chemoresistance would result from a subset of
tumor cells that already exist as cells with the inherent ability to be resistant to chemotherapy,
which are then selected for upon treatment. Induced chemoresistance is a result of a subset of
transcriptomically plastic cells that after chemotherapeutic pressure upregulate networks
responsible for chemoresistance and develop a chemoresistant tumor. Without the barcoding
system, it would be difficult to ascertain the mechanism leading to chemoresistance in SCLC. By
utilizing the barcode system, the barcodes from the cells that form chemoresistant tumors can be
tracked to cells in the pre-chemotherapy tumors, and their transcriptomes can be evaluated for
changes that may have led to the development of chemoresistant tumors. If the transcriptomes
from cells with matching barcodes are the same in the pre- and post-chemotherapy samples, that
would indicate inherent chemoresistance in SCLC. If the transcriptomes of populations with
matching barcodes change after chemotherapy, there would be evidence of induced
chemoresistance after chemotherapy. In the SCLC-N chemoresistant tumors, there is a much
more subtle transcriptomic change from pre- to post-chemotherapy. This is consistent with
reports of SCLC-N tumors being more chemoresistant16. By pairing cellular populations that
share the same barcodes pre- and post-chemotherapy in the SCLC-N tumors as well, we can
ascertain whether the chemoresistance in SCLC-N tumors is inherent, or if there are subtle
changes that lead to induced chemoresistance.
Similarly, there is a transcriptomic shift between the pre-injection samples and the resulting
tumor, particularly in the SCLC-A tumors, indicating a bottleneck event that allowed for a subset
of cells to form the resultant tumor. By matching cells that contain the same barcode in the preinjection and pre-chemotherapy samples, we can evaluate the requirements for cells that are able
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to generate tumors. In the SCLC-N tumors, there is a smaller transcriptomic shift between the
pre-injection sample and the formed tumor, which may indicate increased propensity for these
cells to form tumors.
One of the most commonly upregulated families in the chemoresistant tumors was the cancer
testis antigen (CTA) family. Cancer/Testis Antigens (CTA) are a large class of proteins almost
exclusively expressed in the male germ cells and tumors. CTAs have shown promise as
potentially targetable, unique cancer antigens. For this reason, they make excellent candidates for
immunotherapy such as CAR-T therapy and cancer vaccines77-83,100. CTAs have also been shown
to be diagnostic and prognostic in many cancers, although the particular CTA with prognostic or
diagnostic value seems to be cancer-type specific83,101. In addition to their role as potential
cancer antigens, CT antigens also have oncogenic effects on proliferation, genomic stability,
invasion, colony formation, and resistance to apoptosis, and are associated with cancer stem cells
(Figure 42A)78,79,81,100,102-104. In melanoma and synovial cell carcinoma, a CAR-T targeted to the
CTA NY-ESO-1 led to complete response in a subset of patients, and is an ongoing avenue for
investigation of new therapeutics (Figure 42B)80,105. Another study found the expression of
CTAs to be drivers of breast cancer by increasing the HIF, WNT, and TGFbeta pathways100. In
blood samples from patients with non-small cell lung cancer, the concentration of CTAs were
significantly higher than in patients without cancer, and a panel of CTAs may serve as a bloodbased diagnostic or screening test101. Very little work has investigated CTAs in SCLC. NY-ESO1 has been found to be decreased in the blood of patients with SCLC, and would serve as an
independent diagnostic indicator106. Another CTA, NOLA4, has been found to be significantly
expressed in SCLC cell lines and serum from patients with SCLC, although the functional
impact has not been evaluated107. A clinical trial used cell lysate from a large cell lung cancer
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cell line that is high in expression of CTAs as a cancer vaccine in patients with lung cancers or
thoracic metastasis. Two of the 24 patients in this study had SCLC. Patients developed
antibodies against the CTAs NY-ESO-1, GAGE7, and MAGE-C2. They also observed a
decrease in the number of regulatory T cells and a decrease in the expression of PD-L1 on
tumor-infiltrating immune cells in patients who got the cell lysate vaccine. A follow-up clinical
trial of this study is ongoing to evaluate the utility of a cell lysate vaccine in patients with lung
cancer108. PAGE5 (CT16) has been identified to be expressed in some cancers, and in melanoma
was elevated as an anti-apoptotic gene in response to platinum-based chemotherapy. Expression
of PAGE5 was shown to be pro-survival, and upregulated genes related to melanoma cell
survival in response to chemotherapy84. GAGE2A is another anti-apoptotic CTA, that seems to
be related to treatment resistance in medulloblastoma85,86. CTAs have been identified just once in
SCLC, but have not been investigated109. While the study of CTAs in SCLC has been very
limited, they have shown progress as prognostic, diagnostic, and therapeutic targets in other
cancers, and are a promising avenue of exploration in SCLC.
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Figure 43: Cancer Testis Antigens have oncogenic functions.
A: Multiple CTAs can impact tumorigenesis, and the affect is CTA and cancer type-dependent. From
Gjerstorff et al., Oncotarget, 2015. B: CT scan of a patient with lung metastases (arrowheads) from
synovial cell carcinoma treated with NY-ESO-1-targeted T cells. At 14 months after treatment, a
dramatic response to therapy can be observed by noting the absence of lung metastases. From Robbins
et al., Journal of Clinical Oncology, 2011.
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The CTAs PAGE5 and GAGE2A were highly expressed in the SCLC-A chemoresistant tumors,
and were highly expressed in all of the SCLC-N tumors. I investigated the role of PAGE5 and
GAGE2A in mediating resistance to chemotherapy in SCLC. Treatment of SCLC-A and SCLCN cell lines in culture leads to robust upregulation of PAGE5 and GAGE2A in just a couple of
days, which indicates that they may play a role in mediating cellular response to chemotherapy.
Overexpression of PAGE5 or GAGE2A in SCLC cell lines leads to a decrease in chemotherapyinduced cell death. Expression of PAGE5 or GAGE2A in SCLC cell lines is sufficient to confer
chemoresistance in culture. I knocked down PAGE5 or GAGE2A with an shRNA construct and
found that knockdown of either PAGE5 or GAGE2A does not have any impact on response to
chemotherapy. However, when both PAGE5 and GAGE2A are knocked down via shRNA, cells
are significantly more sensitive to chemotherapy-induced cell death. PAGE5 and GAGE2A in
SCLC act as mediators of chemoresistance, where expression of only one is sufficient to confer
resistance to chemotherapy, but inhibition of both is required to sensitize cells to chemotherapy.
To test the impact of PAGE5 and GAGE2A in conferring chemoresistance in vivo, xenografts
using the shRNA knocked-down cell lines were generated. Many CTAs, including PAGE5 and
GAGE2A, do not have a homologue in mice, so transgenic mouse models are not able to be used
to investigate them, and it may be a reason that CTAs have not been identified in previous SCLC
studies. Xenografts generated from cells with PAGE5 and GAGE2A knockdown seem to have a
durable response to chemotherapy, indicating a role for PAGE5 and GAGE2A in vivo as well.
Human SCLC biopsies stain positive for PAGE5 and GAGE2A, which further solidifies the
association of CTAs with
In this dissertation, I have developed the genetic barcode lineage tracing system in SCLC. For
the first time, we have a glimpse in to the events that lead to tumor initiation, clonal diversity,
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and chemoresistance in SCLC. The bioinformatics pipeline developed in this work represents a
significant advance for the analysis of genetic barcode lineage tracing studies not only for uses in
cancer, but also in other situations where clonal analysis is critical, such as developmental
biology. I have described two distinct populations of cells that arise during tumor formation in
situ that are maintained throughout the life of the tumor, while the relative proportion of cells in
each cluster change during tumor progression. The AP-1 family was significantly upregulated in
the late cluster, and has been validated as being critical for tumor initiation in SCLC. In
xenograft studies, the clonal diversity of two subtypes of SCLC, SCLC-A and SCLC-N. The
SCLC-A tumors exhibit more plasticity and transcriptomic shifts after chemotherapy than the
SCLC-N. I have identified and validated the cancer testis antigens PAGE5 and GAGE2A as
being mediators of chemoresistance in SCLC. Given the clinical success of other CTA-targeted
therapies, this represents a promising avenue towards a new therapy for SCLC.
SCLC is a devastating disease, and very little progress has been made in generating truly targeted
therapeutics. The expansion of the barcoding technology in this dissertation has allowed us to
examine ITH in SCLC with unprecedented resolution for the first time. Identifying the AP-1
network as being responsible for tumorigenesis has provided knowledge of the critical early days
of tumor formation in SCLC. Two targetable antigens, PAGE5 and GAGE2A have been
identified in SCLC for the first time. Their role in mediating chemoresistance could be mitigated
in the future with therapeutic antibodies, CAR-T cells, or even cancer vaccines. This work has
contributed to both the basic and translational science and represents a significant advance
towards a cure for this terrible disease.
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Embryonic stem cells possess the ability to differentiate into all cell types of the body.
This pliable developmental state is achieved by the function of a series of pluripotency factors,
classically identified as OCT4, SOX2, and NANOG. These pluripotency factors are responsible
for activating the larger pluripotency networks and the self-renewal programs which give ES
cells their unique characteristics. However, during differentiation pluripotency networks become
downregulated as cells achieve greater lineage specification and exit the cell cycle. Typically the
repression of pluripotency is viewed as a positive factor to ensure the fidelity of cellular identity
by restricting cellular pliancy. Consistent with this view, the expression of pluripotency factors is
greatly restricted in somatic cells. However, there are examples whereby cells either maintain or
reactivate pluripotency factors to preserve the increased potential for the healing of wounds or
tissue homeostasis. Additionally there are many examples where these pluripotency factors
become reactivated in a variety of human pathologies, particularly cancer. In this review, we will
summarize the somatic repression of pluripotency factors, their role in tissue homeostasis and
wound repair, and the human diseases that are associated with pluripotency factor misregulation
with an emphasis on their role in the etiology of multiple cancers.
THE CORE PLURIPOTENCY NETWORK
Pluripotency factors regulate a host of biological processes essential to establishing the
embryonic state. Of these, three factors, SOX2, OCT4, and NANOG, have been identified as the
three core factors regulating cellular pluripotency1-3. Beginning in the early embryo, SOX2,
OCT4, and NANOG are expressed in the inner cell mass (ICM) of the developing blastocyst and
are required for the maintenance of pluripotency, and upon embryonic differentiation these
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factors are downregulated4-8. These core factors are so vital for the maintenance of a pluripotent
state that they have now become part of the standard reprogramming cocktail for the generation
of induced pluripotent stem (iPS) cells9. OCT4 and SOX2, along with c-MYC and KLF4, are
crucial for the generation of iPS cells, and the gene expression profile of these iPS cells is nearly
identical to that of embryonic stem (ES) cells, illustrating their importance for maintaining the
stem cell phenotype10. Indeed the ability of these reprogramming factors has in part given them
the designation of master regulators, where they can activate target genes even when
epigenetically repressed11,12. Therefore, due to the powerful transcriptional effects of these
pluripotency genes, they must be subject to rigorous regulation throughout development to
restrict their activation and allow for proper development.

SILENCING OF PLURIPOTENCY IN THE SOMA
Given that pluripotency is restricted to the ICM of the blastocyst a mechanism of silencing in
somatic tissues should exist. It has been found that in ES cells the core pluripotency genes are
marked by the activating histone modification histone H3 lysine 4 trimethylation (H3K4me3),
and then during differentiation this mark is replaced by the silencing histone 3 lysine 27
trimethylation (H3K27me3) mark13,14. Concurrent with this regulation of histone methylation,
there is a clear correlation of DNA methylation on the epigenetic regulation of the core
pluripotency genes. The DNA at the promoters of the core genes are typically unmethylated in
the embryonic state, however, they become rapidly methylated during differentiation, although
there are some cases where Sox2 evades DNA methylation14,15. This regulation is mediated in
part by the activity of both DNMT activity in ES cells and the DNA demethylases such as TET1.
Oct4 specifically is methylated both at enhancer and promoter regions during the differentiation
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process and is dependent on DNMT3a and DNMT1 for this methylation16. When Tet1 is
downregulated, the Nanog promoter becomes methylated and it is subsequently silenced17. TET
proteins including TET1 and TET2, and the DNMT3 family are crucial for methylating DNA
during differentiation and silencing of pluripotent genes. In a study evaluating the epigenome of
differentiated and ES cells, the DNA cytosine methylation in ES cells was mostly in a non-CpG
context. These marks were associated with gene bodies and were greatly depleted as cells
differentiated. The reduced non-CpG methylation was associated with lower transcriptional
activity of developmentally relevant genes in differentiated cells, indicating that non-CpG DNA
cytosine methylation might be key for the regulation of developmental genes18. Pluripotency
genes may also be regulated by miRNAs. It was found that let-7 miRNAs suppress self-renewal
in ES cells and their downregulation was able to de-differentiate somatic cells to iPS cells. Let-7
miRNAs are able to directly downregulate Oct4, Sox2, and Nanog and likely contribute to the
stability of the differentiated state19.

TISSUE HOMEOSTASIS AND WOUND HEALING
Pluripotency networks are not only crucial for the differentiation and organogenesis of
embryonic tissues, but there is increasing evidence that tissue homeostasis and regeneration
could involve the temporary acquisition of pluripotent gene networks. To maintain these tissues
rare populations of adult stem cells actively dividing and differentiating20,21. In particular, Sox2,
Oct4, and Nanog are involved in maintaining the plasticity of these adult stem cells.
Sox2 in Homeostasis and Wound Healing
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Sox2 remains expressed in many adult tissues including the sperm cells, cervix, gut, esophagus,
trachea, bronchiolar epithelium, the brain and sensory cells like the retina and taste buds22,23.
These Sox2+ cells originate from Sox2+ progenitors and are essential for the maintenance of these
tissues22. Sox2+ cells have also been found in the adult brain in sites such as the white matter,
cerebellum, and the hippocampus24-26. In the hippocampus, Sox2 is required for the maintenance
of neural stem cells during adulthood26. Beyond maintenance of the adult brain, Sox2 expression
has been shown to be upregulated in response to invasive brain injuries by activation of Notch
and Sonic hedgehog signaling 27,28. Sox2 is also required for the maintenance of many types of
neuroendocrine cells throughout the body29-31.
Similarly, Sox2 expressing cells are present in other non-neural or neuroendocrine tissues in the
adult as well. A population of Sox2 expressing cells is found in the adult pituitary and help it
regenerate in response to injury32-35. There are similar mechanisms throughout the body
including the trachea and the intestinal crypts where Sox2 expressing cells maintain and repair
these tissues36,37. Furthermore, Sox2 is required for osteoblast function and self-renewal38.
Therefore there is a significant role for SOX2 in the development and maintenance of many
tissues outside of the embryonic state.
Oct4 and Nanog in Homeostasis and Wound Healing
Mainly Oct4, sometimes in combination with Nanog, has been shown to be expressed in a
variety of adult tissues, most commonly seen in hematopoietic and mesenchymal progenitors
found in the bone marrow39-43. Oct4 is also found in a wide variety of other progenitors in
different body tissues, yet Oct4 expression is not required for tissue homeostasis in the same way
as Sox244. The one exception is the need for Oct4 expression for the viability of adult germ
cells45,46.
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Although Oct4 itself may not be required for tissue regeneration like Sox2, small populations of
cells in the body that exhibit stem-ness population have been seen. A population of cells called
very small embryonic-like cells (VSELs) has been discovered in many adult tissues that do
express Oct4 and Nanog and are able to differentiate into all the germ layers but not selfrenew47,48. It is unknown if these VSELs play a role in tissue homeostasis in contrast to other
Oct4+ progenitor cells in the adult48.

ABERRANT PLURIPOTENCY FACTOR EXPRESSION IN DEVELOPMENTAL
DISEASE
Due to the importance of the core pluripotency factors in the establishment of ES and iPS cells, it
is no surprise that mutations in these factors can cause developmental diseases. As Sox2 remains
expressed past the blastocyst stage and into organogenesis, mutations in the gene can cause a
multitude of developmental defects (Table 1)23,49. In contrast, Oct4 and Nanog are largely not
expressed after the early stages of development, but they do contribute to the viability of germ
cells50-53. In the past two decades, scientists have attributed many developmental problems to
misregulation of these core factors, predominantly SOX2.
The Role of Sox2 in Early Development
The transcription factor Sox2 is necessary for development from the earliest stages after
conception. It has been shown that most Sox2-/- zygotes arrest as morulas, although a few can
survive to become blastocysts where they fail at implantation7,54. In the blastocyst stage, Sox2 is
expressed as the earliest marker of the inner cell mass, and the trophectoderm54,55 Sox2 continues
to be expressed in the extraembryonic endoderm as well as the primitive ectoderm 7. As the germ
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layers are formed, Sox2 is upregulated in cells that choose the neural ectoderm fate and
suppresses the formation of mesoderm 56.
Sox2 in Neural/Sensory System Development and Disease
Sox2 is present in the neuroectoderm from early stages, and remains expressed in neural stem
cells to promote survival in the central and peripheral nervous system57,58. In early development,
the brain forms normally without Sox2 and no defects are seen at midgestation in the mouse59.
However, mutations in Sox2 do cause defects in postnatal mouse development in the
telencephalon, particularly in the hippocampus dentate gyrus through misregulation of sonic
hedgehog signaling26,60. In later fetal development, Sox2 is strongly expressed in the thalamus
and hypothalamus60,61. It is no surprise that mutations in Sox2 have been known to affect the
formation of the hypothalamus-pituitary system, by causing hypoplasia of the anterior pituitary
and gonadotrophin deficiency, resulting in fertility deficiencies60,62. Mutations in Sox2 have also
been shown to affect eye development, causing anophthalmia or microthalmia63-65. These defects
are caused by misregulation of differentiation in the optic cup by disruption of Notch1 signaling
and Pax6 function which are both orchestrated by Sox2 function63,64,66. Other sensory systems are
affected as well including the development of the cochlea and regulation of WNT signaling to
form taste buds65,67,68. Sox2 mutations can result in these defects occurring together: coloboma,
heart malformation, atresia of the choanae, retarded growth and development, and genital and ear
abnormalities or (CHARGE) syndrome as a result65.
Sox2 in Gut, Lung, Kidney System Development and Disease
Sox2 is involved in the development of other organs, such as the gut where it is essential for
anterior and posterior patterning and guides the tissue towards a gastric fate over an intestinal
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identity69-71. In the development of the foregut, Sox2 is expressed to form the trachea, esophagus,
and the esophageal epithelium70,72. If Sox2 is mutated, this can sometimes result in
anophthalmia,-esophageal-genital syndrome (AEG) where the formation of the esophagus and
trachea is abnormal and these structures fail to separate63,73. Once the lungs have formed, Sox2 is
essential for normal lung branching and the maintenance of lung progenitor cells29,74. Sox2
mutations have also been implicated in chronic kidney disease65,75.
Oct4 in Early Development
Oct4 is present throughout the morula, expressed highly in the inner cell mass, and promotes
differentiation into primitive endoderm76-78. As the blastocyst differentiates into the germ layers,
Oct4 specifies mesoderm while suppressing neural ectoderm56,79,80.
Oct4 in System Development and Disease
Although Oct4 plays an important role in early development, it is silenced in embryonic stem
cells, and not expressed in the development of the organs with the exception of the primordial
germ cells44,52,81. Oct4 is necessary for the switch from the pluripotent stem cells to the germ
cells, thus problems with this mechanism can lead to infertility51-53. Although mutations in Oct4
itself do not cause any developmental diseases directly, the misregulation of many of Oct4’s
binding partners is associated with diseases82.
The Role of Nanog in Development and Developmental Disease
Nanog appears in the late morula, the blastocyst and is expressed in the inner cell mass83. Nanog/-

blastocysts cannot survive, although after implantation Nanog becomes downregulated83,84.

Nanog is commonly expressed temporally and spatially with Oct483,85,86. Similarly to Oct4,
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Nanog is not expressed in the tissues after early development except for the primordial germ
cells where it necessary for the PGCs to mature on the germ ridge50.
ABERRANT PLURIPOTENCY FACTOR EXPRESSION IN CANCER
The role of Sox2 in Cancer
In recent years, much work has begun to elucidate the role and association of Sox2 in cancer in a
vast array of human and mouse tumor types (Table 2). In a chemically-induced model of mouse
squamous cell carcinoma, Sox2 enriched cells were the tumor propagating cells, and conditional
deletion of Sox2 decreased tumor formation and led to regression in existing tumors87. Sox2
expression was required for tumorigenicity of mouse osteosarcoma and knockout of Sox2
decreases the cancer stem cell-like phenotype seen in Sox2+ osteosarcoma cells88. In both human
and mouse bladder cancer, Sox2 is overexpressed in pre-neoplastic and neoplastic tumors, where
the knockout of Sox2 decreased tumor invasiveness89. Given that Sox2 is a pluripotency gene, it
is unsurprising that expression of Sox2 in human glioblastoma multiforme (GBM) cells was able
to direct differentiation in to a stem-like state capable of tumor propagation90. Also in human
glioma and glioblastomas, Sox2 expression had a positive correlation with tumor grade. In this
cohort, Sox2 expression was highest in hypercellular areas with highly proliferative cells91. A
separate study verifies these results by showing that Sox2 is decreased in more differentiated
GBM samples, and overexpression of Sox2 in cell culture leads to increased proliferation and
stemness92. GBM cells in culture are dependent on Sox2 to proliferate and form colonies and
knockout of Sox2 reduced these phenomena93. Human ER-positive breast cancer cells in culture
that were resistant to tamoxifen therapy had high levels of Sox2. In fact, in a cohort of patients
with ER-positive breast cancer, Sox2 was more highly expressed in those who were not
responsive to treatment, compared to patients whose cancer was responsive to treatment. In a
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larger patient set, Sox2 expression was found to be prognostic of poor overall and disease-free
survival94. Despite the high expression of Sox2 seen in patients with ER-positive breast cancer in
Piva et al., patients with sporadic, basal-like breast cancer in a separate cohort had an inverse
relationship between Sox2 expression and ER expression95. In two cervical cancer lines, Sox2
was overexpressed and marked a subset of stem-like cells96. Sox2 has also been found to be
upregulated in liquid tumors such as ALD-positive large-cell lymphoma, in which Sox2
expression imparts a more “plastic” phenotype97. Finally, Sox2 has been implicated in the switch
to androgen resistance and involves the function of the tumor suppressors Rb1 and p5398.
In addition to the studies linking Sox2 expression to cancer phenotypes, a number of studies have
shown an association between expression of Sox2 and clinical outcome. In breast cancer, it was
suggestive that Sox2 expression could be a biomarker of resistance to therapy, as well as poor
overall and disease free survival94. Sox2 expression in head and neck squamous cell carcinoma
was associated with tumor recurrence and poor prognosis99. In tongue squamous cell carcinoma,
Sox2 expression is significantly associated with tumor stage, cell differentiation, and
metastasis100. A large study of patients with gastric cancer who had undergone surgical resection
of the tumor found that Sox2 positivity was correlated with invasion depth, lymph node
metastasis or invasion, and that the prognosis of patients with Sox2 positive cancers was
significantly worse than the prognosis of patients who had Sox2 negative cancers101. In a study of
non small-cell lung cancer samples, Sox2 was significantly overexpressed in cancer cells, and not
in preneoplastic or healthy tissues, although no correlation with histopathological data was seen
in this study102. Interestingly, in synovial sarcoma, Sox2 was expressed at relatively low levels
and had no correlation to clinicopathological data103.
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Much work has shown that Sox2 is expressed in a wide array of cancers. However, the exact
molecular mechanism of Sox2 activation in cancer is unknown, although there are several
hypotheses for how Sox2 drives tumor dynamics. A 2014 study by Justilien et al found an
overexpression of SOX2 by way of amplification of chromosome 3q26 in five human lung cancer
cell lines. Mechanistically, it was found that PKCi, which is also amplified on chromosome
3q26, phosphorylates SOX2, which regulates SOX2 binding to hedgehog acyl transferase
(HHAT). HHAT is crucial for hedgehog ligand binding and activation by SOX2 binding leads to
downstream hedgehog activation. In the lung cancer lines studied, the expression of Sox2,
HHAT, and PKCi were all required for the formation of oncospheres and proliferation in
culture104. Chromosomal amplification of SOX2 has also been implicated in small cell lung
cancer (SCLC)105. The means of Sox2 upregulation may be varied and tissue-specific, however,
as Sox2 can be directly repressed by RB1, loss of Rb1 function is often a driver mutation for
many tumors associated with Sox2 upregulation 98,105-108. However, not all cases of Sox2
upregulation are connected to Rb1 function. In contrast to small cell lung cancer, lung squamous
cell carcinomas are not strongly associated with Rb1 mutation, yet Sox2 is clearly associated
with their growth and maintenance109. In mouse and human skin squamous cell carcinoma
overexpression of Sox2 is observed and was found to be associated with activating histone
marks, when it should be associated with repressive marks in healthy tissue87. One study in
human ALK-positive large-cell lymphoma cells found that Sox2 overexpression, along with
doxorubicin-resistance and more aggressive growth, was triggered by oxidative stress caused by
hydrogen peroxide97. In cervical cancer with upregulations of epidermal growth factor (EGF)
receptor, knockdown of the EGF/PI3K pathway reduced expression of Sox2, suggesting that this
pathway may play a role in the upregulation of Sox2 in cervical cancer. Also in this study, it was
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found that expression of miR-181a-2-3p and let-7i-5p was able to downregulate Sox2 expression,
alluding to a dual role of miRNA and EGF receptor in mediating Sox2 levels96.
The downstream targets of Sox2 activity are also varied and likely tumor-specific. The Sox2
target YAP, a member of the Hippo pathway, was found to be activated in a mouse osteosarcoma
model and was a direct driver of initiation and proliferation of the cancer88. Another pathway
implicated with Sox2 in cancer is Wnt/�-Catenin. In human breast cancer and ALK-positive
large-cell lymphoma, higher levels of Sox2 expression led to higher Wnt signaling, which was
associated with resistance to tamoxifen in breast cancer and doxorubicin in lymphoma and could
propagate the cancer stem cell phenotype94,97. Overexpression of Myc was found to be associated
with the same Sox2/Wnt/�-Catenin signaling axis in lymphoma97. A study in tongue squamous
cell carcinoma also found Sox2-dependent overactivation of the Wnt/�-Catenin pathway, which
was associated with epithelial-to-mesenchymal transition (EMT)100. In head and neck squamous
cell carcinoma, Sox2 directly promoted cancer proliferation by upregulation of cyclin B1 and
increase in SNAIL expression, which is associated with EMT, necessary for metastasis99. An
alternate mechanism found in head and neck squamous cell carcinoma is through Sox2 mediated
expression of AFF4, which is a core component of the super elongation complex. AFF4 levels
changed in parallel with Sox2, and knockout of AFF4 led to decreased proliferation, migration,
and invasion of cells, as well as decreased aldehyde dehydrogenase activity, important for tumor
initiation110. Sox2 may not only exert its tumorigenic properties via upregulation of cancer
progressing pathways, but it also appears to have a role in the downregulation of tumor
suppressors. In GBM cells, Sox2 expression downregulates the tumor suppressors BEX1 and
BEX2, however this effect is likely indirect as there are no SOX2 binding domains in either BEX
protein93.
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In addition to multiple signaling pathways, Sox2 could exhibit its oncogenic effects by regulation
of microRNA expression. Sequencing of GBM cells, showed that that miR-145, miR-143, miR253-5p, and miR-462 expression levels were responsive to Sox2 levels. The implications of some
miRNA expression in cancer has yet to be established but miR-145 is thought to target Sox2 to
downregulate its expression, so overexpression of Sox2 combined with downregulation of miR145 could potentiate the tumorigenic effect of Sox293. In a separate study on breast cancer cell
lines and patient samples resistant to Adriamycin therapy, low miR-129-5p expression was
correlated with treatment resistance and a more aggressive phenotype in culture. Given that miR129-5p binds directly to Sox2, when levels of miR-129-5p were high, levels of Sox2 decreased
and sensitized the cancer cells to treatment111.
While it is clear that Sox2 is upregulated in a number of tumor types, and is likely correlated with
clinical phenotype, more work is needed to determine how Sox2 affects cancer phenotypes.
Given the variety of pathways and associations with Sox2 in cancer, it is possible that the exact
mechanism will be tumor or tissue-of-origin specific.
Oct4 in Cancer
Given the reprogramming power of Oct4, it also warrants investigation in a cancer setting. When
using Oct4 to reprogram fibroblasts to iPS cells, the methylation pattern in early reprogramming
resembles that of cancer cells, and these cells were able to form teratomas with malignant
characteristics in xenografts112. In somatic tissues of adult mice, expression of Oct4 was
sufficient to drive epithelial growths, which are dependent on Oct4 for proliferation. In the
intestines of these animals, Oct4 expression inhibits differentiation of progenitor cells and reverts
them to an embryonic-like phenotype113. In lung adenocarcinoma cells, Oct4 is significantly
elevated and is associated with expression of the stem cell marker CD133, as well as increased
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drug resistance and a higher propensity for EMT114. In non-small cell lung cancer with an
activating epidermal growth factor receptor (EGFR) mutation, Oct4 was also associated with
treatment resistance and expression of CD133115. When using human tumor-derived cell cultures
of lung adenocarcinoma and bronchioloalveolar carcinoma it was found that, when compared to
healthy tissue, only lung adenocarcinoma expressed higher levels of Oct4116. In an analysis of
human prostate cancer lines, Oct4 was highly expressed in a subset of cells that were highly
clonogenic and resistant to treatment with both docetaxel and gamma-radiation. These cells were
CD133+, exhibited a stem-like state in culture, and formed highly aggressive tumors in mice117.
Laboratory based studies of Oct4 in cancer have clearly indicated it is an important factor, as
have studies evaluating clinical correlates. Along with the expression of Nanog and the EMT
marker Slug, Oct4 expression marks high-grade lung adenocarcinomas and is associated with a
worse prognosis for patients114. Also in lung adenocarcinoma, Oct4 was upregulated and
correlated with decreased differentiation, decreased survival, and increased tumor stage with
worse clinical outcomes than Oct4-negative lung adenocarcinoma118. Oct4 was found to be
highly expressed in EGFR-mutant non-small cell lung cancer and may be a marker for treatment
resistance in these patients115. In a separate study of human non-small cell lung cancer, Oct4
expression was associated with poor differentiation, and poor prognosis in patients who
underwent surgical resection102 Oct4 was also overexpressed in ovarian cancer samples and was
correlated with histological grade119.
Oct4 has been shown to activate a number of downstream pathways when implicated in cancer.
Oct4 overexpression in mice that resulted in epithelial growths showed increased �-catenin
signaling in these cells113. In human ovarian cancer, follicle stimulating hormone (FSH) has
previously been shown to inhibit apoptosis, and has found to be dependent on the presence of

118

Oct4. Oct4-mediated expression of FSH, leading to apoptotic inhibition also increased the
expansion of ovarian stem-like cancer cells and upregulated the expression of other cancerrelevant genes like Notch, Sox2, and Nanog120. Oct4 was also found to regulate the rate of
apoptosis in breast cancer by a different mechanism. In breast cancer cell lines, Oct4 expression
regulated the expression of p16INK4a, p14ARF, Bcl-2/Bax, and p53, which may collectively lead
to Oct4-mediated cell cycle progression and decreased rates of apoptosis121.
It is possible that Oct4 may also exert its effect through regulation of long non-coding RNAs
(lncRNA). In a study of human lung cancer samples, multiple lncRNAs were found to be direct
transcriptional targets of Oct4. The most relevant of these were nuclear paraspeckle assembly
transcript 1 (NEAT1), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), and
urothelial carcinoma-associated 1 (UCA1). NEAT1 or MALAT1 overexpression led to cancer cell
proliferation, migration, and invasion, and knocking down NEAT1 or MALAT1 decreased cancer
cell growth and motility. These lncRNAs were so important to cancer progression that coexpression of both, along with Oct4 was predictive of poor prognosis in lung cancer patients122.
Ordinarily, Oct4 would be regulated by degradation by the ubiquitin proteasomal system (UPS),
however, it is clear that in a cancer state, there is some level of misregulation that occurs. In
healthy tissues this is mediated by OCT4 binding with CAV-1, a scaffolding protein, which
allows for the degradation of OCT4 via UPS. In human lung cancer cells, nitric oxide (NO)
facilitates the phosphorylation of CAV-1 by AKT, which subsequently does not allow OCT4 to
complex with it, and therefore OCT4 does not get degraded via UPS. It is possible that the NO
upregulation seen in many cancers is causal for increased levels of OCT4123. Another potential
mechanism for regulation was shown in lung adenocarcinoma cells. Here, BEX4, was more
highly expressed in cancer samples than in healthy tissue, and was shown to positively regulate
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the expression of Oct4 and was required for proliferation of these cells. Interestingly, BEX4
expression was regulated by mTOR activation and suggests a role for an mTOR/BEX4/Oct4
cascade in lung adenocarcinoma124.
Intriguingly, one study has uncovered a positive role for Oct4 overexpression in cancer. In a
large study of gastric cancer patients who underwent surgical resection, tumors that were Oct4
negative correlated with invasion depth and lymph node metastasis or invasion. In this study,
Oct4 negative patients had significantly worse outcomes than patients whose tumors were Oct4
positive. The authors suggested that Oct4 might suppress tumorigenesis, but in light of the strong
links to Oct4 expression and poor outcomes, it is probable that the positive effect of Oct4
expression observed in this study is specific to gastric cancer101.
Nanog in cancer
Unsurprisingly, the third pluripotency factor covered in the scope of this review, Nanog, has also
been implicated in cancer. In a mouse model of mammary cancer, Nanog signaling accelerated
tumor growth and caused tumors to be highly metastatic125. Nanog is overexpressed in human
colorectal carcinoma cells, and it was found that these cells in culture have a high propensity
towards a stem-like state. Human colorectal carcinoma cells readily form spheroids in culture
and expression levels of Nanog increase greatly as the spheroids form. Inhibition of Nanog in
this model decreased proliferation and G2-cell cycle related protein activation120. Studies with
Nanog positive human hepatocellular carcinoma cells in culture demonstrated that Nanog
positive cells readily differentiate into a wide variety of cancer cells, indicating the stemness of
Nanog positive cells. These cells are highly invasive and metastatic, as well as resistant to
chemotherapy126. In lung adenocarcinoma, Nanog was highly expressed and overexpression
increased the CD133+ population in culture, as well as increasing drug resistance and EMT114.
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Like Sox2 and Oct4, Nanog also has strong clinical correlates. In hepatocellular carcinoma,
expression of Nanog was correlated with a worse clinical outcome126. In a study of human
colorectal carcinoma cases, NANOG expression was associated with liver metastasis, which
could make NANOG a marker of liver metastasis in colorectal carcinoma120,127. Also in colorectal
cancer, NANOG was more highly expressed in CD133+ tumor cells than in CD133− tumor cells,
and expression was related to tumor grade, lymph node metastasis, and tumor stage using the
TNM (tumor extent, node invasion, presence of metastasis) staging system127. NANOG
expression in human cervical cancer was associated with immune evasion and was found to be
positively correlated with outcome and disease stage128. A study evaluating Nanog expression in
lip squamous cell carcinoma, actinic cheilitis, and normal lip epithelium found that Nanog was
more highly expressed in the pre-cancerous actinic chelitis, and in lip squamous cell carcinoma,
when compared to normal epithelium. It is therefore possible that Nanog has a role in the switch
from healthy to precancerous, to cancerous tissue129. Patients with gastric adenocarcinoma had a
higher expression of NANOG in their excised tumors than in healthy tissue. Additionally, the
expression of NANOG was correlated with tumor stage, lymph node status, extent of infiltration,
differentiation, and poor prognosis130. A large meta-analysis of gastrointestinal luminal cancer
found that NANOG expression was associated with patient gender, depth of infiltration
differentiation, TNM stage, and poor overall and disease-free survival, which implicates NANOG
as a potential biomarker for gastrointestinal luminal cancer131. Surprisingly, a tissue microarray
of human esophageal squamous cell carcinoma samples showed that increased expression of
NANOG was associated with favorable prognosis and response to cisplatin132. Given the above
evidence, it is puzzling that NANOG was favorable in these cases. Nevertheless, it is possible
that the effect of Nanog is tumor or tissue specific and warrants further research.
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Nanog may exert its tumorigenic effects via a variety of downstream targets. In a transgenic
mouse model of breast cancer, overexpression of Nanog alone is not sufficient to induce cancer.
Instead, when in combination with an upregulation of Wnt-1, Nanog was able to promote the
growth of highly metastatic tumors. In this model, Nanog was found to be associated with the
expression of a number of tumor-relevant genes, including EMT markers and PDGFRa, which
can also drive tumorigenesis, angiogenesis, and metastasis, corroborating Nanog’s effect in
breast cancer125. In Nanog-positive hepatocellular carcinoma cells, insulin-like growth factor 2
(IGF2) and insulin-like growth factor receptor (IGF1R) were upregulated, and their levels
sensitive to changes in Nanog expression. Nanog expression levels decreased when IGF1R was
knocked out, indicating the presence of some sort of feedback loop along this signaling axis126.
In a study of a variety of human cancer types, NANOG in precancerous and cancerous cervical
tissue was related to the expression of TCL1A and phosphorylated AKT, which have a role in
promoting chemotherapy resistance and immune evasion128. Interestingly, in human colorectal
carcinoma, NANOG knockdown decreased expression of SOX2 and OCT4, indicating that the
probable feedback loop between these three factors is relevant in cancer as well119.
How Nanog becomes expressed in cancers is still largely unknown, but some work has been
done to elucidate a mechanism. In ovarian cancer, both NANOG and the androgen receptor (AR)
are highly expressed. Given that the androgen 5a-dihydrostestosterone (DHT) activated NANOG
transcription, it is possible that AR induces NANOG transcription. Cells given DHT had higher
tumorigenesis, proliferation, migration, and colony and sphere formation, all phenotypes
observed in NANOG-high cancers133.

SUMMARY AND OUTSTANDING QUESTIONS
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While a great body of work has elucidated the role of the pluripotency factors in ES and iPS cells
and there still requires a larger analysis of the roles of the core pluripotency network outside of
pluripotency. While some pluripotency factors have been studied outside of pluripotency, such as
the role of Sox2 in neural stem cells, there still remains to be a rigorous comparison of
downstream network activation in non-pluripotent tissues compared to pluripotent stem cells.
The information gathered to date indicate that there are indeed different roles for pluripotent
genes in postnatal cell types that are different from their roles ES cells. This brings forth an
interesting question: if exogenous pluripotent gene expression (such as those expressed during
iPS reprogramming) are able to reprogram a cell to an ES-like state, why is it that adult cells that
express core pluripotency genes not also mimic ES cells? Is it truly the combination of
recombination factors alone, or are there some cell type-specific effects that modulate the
network of genes activated by these pluripotency genes in contrast to the standard definition of a
master regulator134? Furthermore, what contribution could these cell type-specific effects have on
the outcome of pluripotency factor expression in a cell, whether it be a normal response to injury
or a pathological response such as the formation of a tumor? This requires a greater
understanding of the upstream regulators of the pluripotency factors in somatic tissues to
understand these seemingly diverse roles of regeneration or disease.
The function of the core pluripotency genes, SOX2, OCT4, and NANOG, is of vast importance in
understanding early development, embryonic stem cell function, and cellular reprogramming of
iPS cells. However, their roles are not limited to early development. They are responsible for the
maintenance of many adult tissues, and their regeneration after wounding. Importantly, they are
key to understanding multiple pathologies, including cancer. An understanding of how these
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genes work outside of a pluripotent context will be critical to guiding new therapies to the clinic
to treat many pathologies and to perhaps enhance wound regeneration.
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Table 1 – Developmental disorders linked to pluripotency factor misregulation
Disorder
Anothplamia,esophageal-genital
syndrome
CHARGE syndrome
Cochlear malformation
Chronic kidney disease
Dentate gyrus
hypoplasia
Hypogonadotropic
hypogonadism
Taste sensory defects

Pluripotency
Factors
Sox2

Gene Networks

References

Notch, Pax6

63-65,73

Sox2
Sox2
Sox2
Sox2

Chd7
Wnt

65

Shh

26

Sox2

Wnt

60

Sox2

Wnt

68

67
65,75

Table 2 – Cancers linked to pluripotency factor misregulation
Cancer

Pluripotency
Factors
SOX2
SOX2,
OCT4,
NANOG

Roles

Cervical cancer

SOX2,
NANOG

Maintain CSCs, immune
evasion

Colorectal cancer

NANOG

Esophageal cancer
Gastric cancer

SOX2
SOX2,
OCT4,
NANOG

Maintain CSCs, proliferation,
drug resistance
Differentiation
Tumor grade, metastasis, poor
survival

Bladder cancer
Breast cancer

Gene Networks

Tumor Invasiveness
Tamoxifen resistance, poor
survival, proliferation,
metastasis
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References
89

Wnt/B-Catenin,
miR-129-5p,
p16INK4a,
p14ARF, Bcl2/Bax, p53
EGF/PI3K, miR181a-2-3p, let-7i5p, AKT

94,95,111,121,125

96,128

120,127
108

IGF2, IGF2R

101,130-132

Glioblastoma

SOX2

Hepatocellular
carcinoma
Lung cancer (non-small
cell)

NANOG

Lung cancer (small cell)
Lung cancer (squamous)
Lymphoma
Osteosarcoma
Ovarian cancer
Prostate cancer
Squamous cell
carcinoma (head and
neck)
Squamous cell
carcinoma (skin)

Maintain CSCs, tumor
propagation, proliferation,
dedifferentiation
Maintain CSCs, metastasis,

BEX1 and BEX2,
miR-145, miR-143,
miR-253, miR-462

SOX2,
OCT4,
NANOG
SOX2
SOX2
SOX2

Tumor progression, drug
resistance, EMT, poor survival

CD133, EGFR,
NEAT1, MALAT1

SOX2
OCT4,
NANOG
SOX2, OCT4
SOX2,
NANOG

Maintain CSCs, proliferation
Tumor progression,
proliferation
Maintain CSCs, drug resistance
Tumor reoccurrence, poor
survival, metastasis

SOX2

Maintain CSCs, tumor
propagation, proliferation,
survival, adhesion, invasion
and paraneoplastic syndrome

Proliferation
Proliferation
Dedifferentiation

90-93

126
102,114116,118,122-124
109
105

Hedgehog
Wnt/B-Catenin,
Myc
Hippo/YAP
FSH, Notch, AR

104

AR, CD133
Wnt/B-Catenin,
Cyclin B, SNAIL,
AFF4
Epigenetic
regulation

98,117

97
88
119,133

99,100,110,129
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Abstract
Although many cancer prognoses have improved in the past fifty years due to advancements in
treatments, there has been little improvement in therapies for small cell lung cancer (SCLC). One
promising avenue to improve treatment for SCLC is to understand its underlying genetic
alterations that drive its formation, growth, and cellular heterogeneity. RB-loss is one key driver
of SCLC, and RB-loss has been associated with an increase in pluripotency factors such as
SOX2. SOX2 is highly expressed and amplified in SCLC and has been associated with SCLC
growth. Using a genetically engineered mouse model, we have shown that Sox2 is required for
efficient SCLC formation. Furthermore, genome-scale binding assays have indicated that SOX2
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can regulate key SCLC pathways such as NEUROD1, and MYC. This data suggests that SOX2
can be associate with the switch of SCLC from an ASCL1 subtype to a NEUROD1 subtype.
Understanding this genetic switch is key to understanding such processes as SCLC progression,
cellular heterogeneity, and treatment resistance.

Implication Statement
Understanding the molecular mechanisms of SCLC initiation and development are key to
opening new potential therapeutic options for this devastating disease.

Introduction
Small cell lung cancer (SCLC) is a devastating disease with markedly low survival rates,
rapid metastasis, and almost invariable resistance to therapy. Patients who are stricken by this
disease face a 6% two-year survival rate, while most will succumb less than a year after
diagnosis (1, 2). Despite this alarming statistic, the standard of care for treating SCLC has
remained essentially the same for the past 40 years and few innovations have been approved for
this disease. First line treatments still rely primarily on platinum-based chemotherapy that often
leads to treatment refractory tumors and poor patient outcomes (3-5). Recently immunotherapy
options have been available for SCLC; however, while the results have been encouraging in
select individuals, the patient responses have been generally poor (6). Therefore, in the pursuit of
new therapies for SCLC, we have sought to understand the genetic factors underlying SCLC
dynamics.
On a genetic level, SCLC is both rather simple and complex. It is simple in that the genetic
drivers of SCLC are relatively clear. Patients have an almost invariable loss of the tumor
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suppressors p53 (TP53) and RB1 (RB) (7-9). Intriguingly, established SCLC can be genetically
complex considering that, even with almost identical driver mutations, SCLC can be subdivided
into four main subtypes defined by the function of key genetic regulators, ASCL1, NEUROD1,
POU2F3, and YAP1 (10-13, reviewed in: 14). Critically linked to the regulatory networks of the
ASCL1 (SCLC-A) and the NEUROD1 (SCLC-N) subtypes is the role of the MYC family of
oncogenes. MYC (cMYC) is highly expressed and a determining factor for the SCLC-N subtype
(15). MYCL (L-Myc) rather, is predominantly expressed in SCLC-A, and is key to SCLC-A
growth (7, 11, 16, 17). While MYC family regulation is important to SCLC growth and
development (18), how MYC family members are regulated in SCLC is currently unclear (19).
The question of how a tumor with such homogenous driver mutations (RB1- and p53-loss)
can lead to the diversity of genetic heterogeneity observed in SCLC remains unanswered. One
clue to address this question can be found in the nature of the initiating mutations themselves.
Beyond its role in regulating the G1/S checkpoint, RB also plays a multitude of roles in
regulating gene expression (20-22). One of the genes regulated by RB is the transcription factor
SOX2 (23). Known primarily as a pluripotency factor, SOX2 is also a key master regulator of
neural and neuroendocrine cell types (24-28). As a master regulator, SOX2 influences cell
identity early and widely in cell fate decisions. Indeed, SOX2 is commonly amplified in SCLC
(7). Pulmonary neuroendocrine cells are the predominant cell of origin for SCLC (29), therefore
it is possible that SOX2 upregulation in neuroendocrine cells following RB1-loss induces stem or
progenitor genetic networks that help to drive oncogenesis. To that end, we generated a
conditional knockout mouse in which we could perturb Sox2 activity in a well-characterized
SCLC mouse model to assess the consequence of Sox2-loss on SCLC formation. Combined with
a genome-wide investigation into SOX2 transcriptional regulation in SCLC, we observed that
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SOX2 is indeed required for SCLC formation and regulates key genetic regulators of SCLC
including NEUROD1 and members of the MYC family.

Materials and Methods
Ethics statement
Mice were maintained according to the guidelines set forth by the NIH and were housed in the
Sanford Research Animal Research Center, accredited by AAALAC using protocols reviewed
and approved by our local IACUC.
SCLC mouse tumor initiation
We modeled SCLC in the Rb1lox/lox, p53lox/lox, p130lox/lox, Rosaluc (RPR2) mouse line (30), which
readily develop SCLC after a few months, and added Sox2 +/+,+/lox, or lox/lox alleles (Jackson
Laboratories Stock #013093)(31). To study SCLC tumor initiation, we injected Cre-recombinase
adenovirus (Ad5-CMV-Cre, Baylor Vector Development Lab, 0.91 �L of a 5x1012 pt/mL viral
preparation used per mouse) into the mouse lungs by intratracheal intubation to excise the loxflanked genes (32). The mice were assigned to either a six-month cohort, a three-month cohort,
or the survival curve. Mouse lungs, livers, and any other metastases were harvested for
immunohistochemistry. Tumors were screened in a blinded manner by an independent
pathologist.
SCLC lung and liver immunohistochemistry
The Sanford Research Histology & Imaging Core performed the immunohistochemistry for this
study. The mouse lungs, livers and tumors were stained with H&E, for SOX2 (Abcam ab92494,
1:100), calcitonin gene related peptide (CGRP, Sigma C8198, 1:2,000), anti-phospho-histone H3
(pH3, EMD Millipore 06-570, 1:500), cleaved caspase 3 (CC3, Cell Signaling 9664, 1:100), ki67
(Biocare CRM325, 1:100), ASCL1 (Abcam ab74065, 1:500), and MYC (c-MYC, Invitrogen
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MA1-980, 1:100) (Supplemental Table S4). To computationally assess tumor burden and feature
characteristics, we digitized each slide using an Aperio VERSA slide scanner. The five images
from each sample (H&E and SOX2, CGRP, ki67, pH3, and CC3 IHC) were registered using the
Register Virtual Stack Slices Plugin in FIJI/ImageJ (33). We then used CellProfiler (34) to count
the tumors and features. The H&E staining was used to identify tumors, then the intensity of IHC
staining for the markers SOX2, CGRP, ki67, pH3, and CC3 was determined for the
corresponding tumor areas in the other virtual slide images. Registration and CellProfiler scripts
are available on the Kareta Lab website (https://research.sanfordhealth.org/researchers-andlabs/kareta-lab).
SCLC cell lines
We used the murine SCLC cell lines KP1 and KP3 (Rb1lox/lox; p53lox/lox) and the human SCLC
lines NJH29 (H29), NCI-H82 (H82), NCI-H1836 (H1836), and NCI-H209 (H209) (30, 35). The
cells were maintained in suspension and cultured in RPMI with 10% bovine growth serum and
penicillin/streptomycin. All cell lines regularly tested negative for mycoplasma contamination.
Lentiviral transduction and cell assays
We made the lentivirus for the shRNA-mediated knockdown using the packaging plasmids
VSVG, pMDL, and RSV in 293T cells, transfecting them with PEI with a nearly 90%
transduction rate. Resulting lentivirus was concentrated using Lenti-X Concentrator (Takara Bio,
Inc.) and titered for reproducible transductions. Controls consisted of an empty pSicoR vector or
a pSicoR vector containing a shRNA to Luciferase (23). Transduced cells were selected for by
culture with Puromycin for 5 days. We measured cellular viability after SOX2 knock down with
an alamar blue assay, and the levels of apoptosis with Annexin V staining combined with flow
cytometry. qPCR was used to confirm the knock down of Sox2 in the cells. Cas9-mediated
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knockdown of SOX2 was achieved by cloning a SOX2 gRNA sequence
(ATTATAAATACCGGCCCCGG) into the TLCV2 inducible lentiviral Cas9 vector (36), which
was packaged in to lentivirus using the methods above. Transfection was achieved using
Lipofectamine 3000 (ThermoFisher Scientific) according to the manufacturer’s protocol. To
enhance transfection efficiency, after adding the transfection mix the cells were processed
according to a modified spinfection protocol where they were centrifuged at 940 xg for 2 hours
at room temperature. Mock controls were Lipofectamine-treated and spinfected cells that were
processed the same but without the presence of the DNA vector. Due to high transfection
efficiencies (typically greater than 70%), cells were neither selected nor sorted to minimize
stress.
Chromatin Immunoprecipitation (ChIP) and CUT&RUN Assays
In preparation for HA-RB1�CDK chromatin immunoprecipitation, cells were transfected with
pCMV-HA-hRb1-delta-CDK (Addgene, #58906) using Lipofectamine 3000 (ThermoFisher).
ChIP for HA-RB1�CDK was performed as previously described (23) with several additional
optimizations (37). The alternative swelling buffer was used for cell lysis. Chromatin was
sonicated using a ME220 (Covaris, Inc.). ChIP-grade Protein AG magnetic beads (Pierce) were
pre-blocked with BSA and salmon sperm DNA for 15 minutes on a rotating platform at 4oC. The
chromatin was pre-cleared before being diluted and incubated with an anti-HA antibody (Sigma
H6908, 4 �g) for immunoprecipitation. The antibody-chromatin complexes were incubated with
blocked beads for 2 hours at 4oC on a rotating platform prior to washing two times each with
low-salt, high-salt, and LiCl wash buffers.
CUT&RUN assays were carried out according to the protocol (Version 3) published by Janssens
and Henikoff (38) which is based on the original protocol developed by Skene et al. (39), using
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the CUTANATM pAG-MNase (EpiCypher), and concanavalin-A coated beads (BioMag Plus
#86057). The optional high-calcium/low-salt conditions were included to prevent premature
chromatin release after digestion. Both ChIP and CUT&RUN assays were performed using
SOX2 antibodies from both EMD/Millipore (17-656) and R&D Systems (AF2018). ChIP and
CUT&RUN libraries were analyzed on an Agilent Bioanalyzer System by the Sanford Research
Functional Genomics & Biochemistry Core and sequenced at the Sanford Burnham Prebys
Genomics Core. Both ChIP and CUT&RUN reads were aligned to the hg38 genome build using
Bowtie 2 version 2.3.4.3 (40) and peaks called using MACS2 version 2.1.2 (41). As described by
the authors of CUT&RUN, the top 99.5th percentile of peaks after sorting by q-values (including
peaks with the same q-value at cutoff) were selected for further analysis (39). HOMER was used
for heatmap generation and motif enrichment (42), Diffbind was used for differential peak
identification and PCA visualization (43), and Ingenuity Pathway Analysis for network analysis
(QIAGEN Inc.). Weighted gene co-expression network analysis was performed using the
WGCNA package from Bioconductor (44). RNA-seq data was analyzed using DESeq2 (45).

Results
Sox2 is critical for SCLC tumor initiation
To investigate if Sox2 is required for the formation of SCLC, we bred a mouse line containing a
conditional Sox2 allele (Sox2lox/lox) to the RPR2 [Rb1lox/lox; p53lox/lox; Rbl2(p130)lox/lox] mouse
model of SCLC (Fig. 1A) (29, 30, 46, 47). With the addition of the conditional Sox2 allele, we
therefore named this line RPR2S. Tumors from RPR2 mice display all the common hallmarks of
human SCLC, mainly the same histological characteristics as scored by an independent
pathologist, rapid metastasis, and chemoresistance (30, 47, 48). To overcome the dramatic
effects of global Rb1- and p53-loss in the mouse, we localized Cre-mediated recombination by
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an intratracheal instillation of a Cre-expressing adenovirus (Adeno-CMV-Cre-GFP) to target
recombination specifically to the lung epithelium (49). As expected, we observed early lesions
around 3-months, with a robust tumor burden 6-months after Cre-recombination (30).
By utilizing a breeding strategy that generates all three allelic combinations of Sox2: Sox2+/+,
Sox2+/lox, and Sox2lox/lox (Supplemental Table S1), we were able to query if one or both alleles of
Sox2 are involved in SCLC formation. Three and six months after Adeno-Cre tumor initiation,
Rb1lox/lox; p53lox/lox; p130lox/lox mice showed a sizeable number of tumor foci displaying the
histological characteristics of SCLC. However, the RPR2S mice had a nearly complete loss of
SCLC foci observed at the same timepoint (Fig. 1B). To fully characterize these tumors and
ensure complete Sox2 loss in the RPR2S mice, we optimized immunohistochemistry staining and
an unbiased image analysis pipeline using ImageJ and CellProfiler (34) resulting in a thorough
statistical analysis of the number and marker expression in the RPR2 tumors compared to the
few RPR2S tumors (Figs. 1C and 1D, Supplemental Fig. S1). The RPR2 tumors showed typical
SCLC histology including high Cgrp expression, indicative of a neuroendocrine tumor type, and
highly proliferative cells as indicated by ki67 and phospho-Histone H3 (pH3) staining (50)
(Supplemental Fig. S1). At 6 months, there were a handful of very small tumors observed in the
Rb1lox/lox; p53lox/lox; p130lox/lox; Sox2 lox/lox mice (Fig. 1D and Supplemental Fig. S1), although a
sizeable number of these showed immunoreactivity to SOX2 antibodies, indicating that they are
the result of incomplete Cre function. However, a small minority of SCLC tumors can initiate
without Sox2, indicating that Sox2 activity may not be absolutely necessary in some SCLC
tumors or tumor subtypes. However, those tumors that grew even when Sox2 was deleted were
markedly smaller in size than the Sox2+ tumors (Supplemental Fig. S1D). Importantly, we
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observed a significant lengthening of the lifespan of the Rb1lox/lox; p53lox/lox; p130lox/lox; Sox2lox/lox
mice (Fig. 1E), compared to Sox2-expressing controls.
SOX2 is required for the growth of established SCLC lines
The results indicating Sox2 function in the initiation of SCLC tumors in mice led us to
investigate if Sox2 is required in established tumors. We utilized shRNA-mediated knockdown to
reduce SOX2 expression in both mouse and human SCLC cell lines. We were able to achieve a
~60-90% knockdown of SOX2 by RT-qPCR (Supplemental Fig. S2A). We observed that
knockdown of SOX2 in both mouse and human cell lines significantly reduces the growth of
these cells in culture compared to mock-transduced cells (Fig. 2A), similar to a previously
reported SOX2 knockdown in human SCLC cell lines (7). Concurrent with a loss of cellular
viability, we observed an increase in the number of apoptotic cells upon SOX2 knockdown
(Supplemental Fig. S2B). As RB1-loss is one of the primary genetic drivers of SCLC (7, 9, 47),
and the RB protein can bind to and repress the Sox2 locus in fibroblasts (23), we set out to
investigate if RB is capable of repressing SOX2 in SCLC to indicate if RB-loss in SCLC could
be the driver of SOX2 upregulation. To this end, we overexpressed an RB1 transgene in human
SCLC cell lines in which the CDK phosphorylation sites have been mutated (RB1�CDK) to
render RB resistant to CDK inactivation (51). Overexpression of RB1�CDK greatly reduced the
viability of human SCLC cell lines (Fig. 2B)(52). Furthermore, overexpression of RB1 resulted
in the repression of Sox2 (Fig. 2C). By chromatin immunoprecipitation (ChIP) we tested if
RB1�CDK binds to the promoter or the two known proximal SOX2 enhancers, SRR1 and SRR2
(53). Indeed, we do observe significant enrichment of RB1�CDK-bound regions at the SOX2
promoter and the downstream SRR2 enhancer (Fig. 2D). Finally, overexpression of SOX2-t2aGFP rescued the repression of RB1�CDK growth-inhibited SCLC cell lines (Fig. 2E,
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Supplemental Fig S2C). Together these data confirm that SOX2 is required for SCLC tumor
growth and that SOX2 expression is most likely a consequence of RB1-loss.
SOX2 regulates key SCLC pathways
To observe the genomic localization of SOX2 in human SCLC cell lines, we performed both
ChIP and Cleavage Under Targets and Release Using Nuclease (CUT&RUN) (39) using the
endogenous SOX2 from both H1836 and H29 cells. While SOX2 ChIP allowed for broad
localization studies, we found that SOX2 CUT&RUN was much more sensitive for comparative
genomic localization studies due to the lack of chemical crosslinking and the release of SOX2bound DNA due to SOX2 antibody:ProteinA/G:MNase complexes rather than sonication. We
observed a very similar localization of SOX2 in both cell lines (Fig. 3A, Supplemental Fig. S3,
Supplemental Table S3). Unbiased motif enrichment of the SOX2 peaks identified an HMG
binding domain as the most highly enriched motif (Fig. 3B). The HMG domain is the DNAbinding domain of the SOX family of proteins therefore, the presence of HMG motifs validates
the specificity of the SOX2 localization (54). As expected for a neuroendocrine tumor, and with
the known role of SOX2 in the regulation of neurogenesis (55, 56), the top ontology terms for the
SOX2 adjacent genes were related to neural development and function (Fig. 3C). To assess if the
binding topology of SOX2 in SCLC is similar to other SOX2-expressing cells, we compared the
binding similarity by read counts for SOX2 datasets from human embryonic stem (ES) cells,
induced pluripotent stem (iPS) cells, neural stem cells (NSCs), and glioblastoma (57-60). We
observe that SOX2 binding in SCLC is distinct from both NSCs and pluripotent cells (ES and
iPS cells). The closest binding profile to SCLC was glioblastoma therefore the function of SOX2
in cancer may be distinct from its role in normal cellular development (Fig. 3D).
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The genes that are bound by SOX2 appear to show a biphasic distribution of high- or lowexpression, indicating that they are either upregulated or repressed by SOX2 (Fig. 3E,F,
Supplemental Fig. S4). Indeed, SOX2 can either repress or transactivate target genes based upon
the cofactors recruited (54, 61, 62), and it appears these two roles of SOX2 are maintained in
SCLC. To better describe the genetic networks that are regulated by SOX2 in SCLC we
performed a weighted gene co-expression network analysis (WGCNA) to identify the gene
networks co-expressed with SOX2 using the SCLC cell lines in the Cancer Cell Line
Encyclopedia (63, 64). The WCGNA analysis identified multiple modules that are co-expressed
with SOX2 (Supplemental Fig. S5, S6). The most highly upregulated module with SOX2
contained ASCL1, a known regulator of classic SCLC (10, 11, 14)(Fig. 3G). The most
downregulated module identified contained a MYC network, which is associated with the variant
state of SCLC (15) (Fig. 3H).
SOX2 regulates SCLC-subtype specific specification
To further investigate the result that high levels of SOX2 favors ASCL1 gene modules and is anticorrelated with MYC gene modules (Fig. 3G) we investigated if SOX2 expression favors the
ASCL1 SCLC subtype. We performed unbiased clustering of CCLE SCLC cell lines based on
their expression of ASCL1, NEUROD1, YAP1, POU2F3, MYC, and MYCL (Fig. 4A). The cell
lines generally clustered by subtype and SOX2 specifically clustered with the ASCL1 subtype. As
it is unclear if the ASCL1-SOX2 module (Fig. 3G) is due to direct SOX2 regulation of ASCL1
or a correlation due to high SOX2 levels in the SCLC-A subtype cell lines (Supplemental Fig.
S6), we set out to determine if the regulation of the SCLC subtype-specific factors ASCL1 and
NEUROD1 is directly regulated by SOX2. Overexpression of SOX2-t2a-GFP in two SCLC-A
(H1836 & H209) and two SCLC-N (H29 & H82) cell lines does not appear to perturb ASCL1
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levels, but does result in significant downregulation of NEUROD1 (Fig. 4B, Supplemental Fig.
S7). We observed similar changes at the protein level, although levels of NEUROD1 were
marked lower in H1836 and H209 cells (Fig 4D). We then used an inducible Cas9-mediated
knockdown of SOX2 rather than shRNA-mediated knockdown to observe the rapid effects of
target gene expression after Cas9 induction, which results in significant SOX2 knockdown
(Supplemental Fig. S8A). In contrast to SOX2 overexpression, we observed a significant
upregulation of NEUROD1 (Fig. 4C, Supplemental Fig. S8A). To test if regulation of
NEUROD1 by SOX2 is direct we performed ChIP of SOX2. We observed significant binding of
SOX2 at the NEUROD1 and MYC promoters (Fig. 4E, Supplemental Fig. S8B). Therefore, it
appears that SOX2 does not directly regulate ASCL1; however, it is associated with the
progression of SCLC tumors to the NEUROD1 state.
SOX2 directly regulates MYC and MYCL in the ASCL1 and NEUROD1 SCLC Subtypes
With the observation that SOX2 potentially regulates MYC networks in SCLC (Fig. 3H), we
investigated if SOX2 directly regulates the MYC family in SCLC. We observed binding of
SOX2 to both MYC and MYCL in SCLC from the CUT&RUN data (Figs. 3A and 5A). Both
MYC and MYCL are expressed in SCLC, with MYCL predominantly expressed in the SCLC-A
subtype and MYC expressed in the SCLC-N subtype (14-16). Interestingly, SOX2 appears bound
at MYCL in H1836 cells, which are of the SCLC-A subtype and is bound at MYC in H29 cells,
which are of the SCLC-N subtype (Supplemental Fig S7)(65). This is consistent with a role for
SOX2 to activate these genes in their respective SCLC subtype. Overexpression of SOX2 in both
SCLC-A and SCLC-N cells further supports a role for SOX2 in the regulation of MYC and
MYCL. When SOX2-t2a-GFP is transfected into the SCLC-A cell lines H1836 and H209, we
observed a downregulation of MYC at both the mRNA (Fig. 5B) and protein levels (Fig. 5C and
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5D). Rather, in the SCLC-N lines H29 and H82, there is significant downregulation of MYCL
upon SOX2 overexpression (Fig. 5B) and an apparent, but not significant increase in the protein
levels of MYC (P=0.0724), perhaps not reaching significance due to the already elevated levels
of MYC in these cell lines (Supplemental Fig S7). This indicates that overexpression of SOX2, in
contrast to normal levels of expression (Fig. 5A), is repressive at either MYC or MYCL yet still
favoring MYCL expression in the SCLC-A subtype and MYC expression in SCLC-N. We tested
for either ASCL1, NEUROD1 or MYC expression in the tumors from the RPR2S mice, and
observed that Sox2+ tumors display high ASCL1 and low NEUROD1/MYC staining, which is
expected as the RPR2 mice predominantly form tumors of the SCLC-A subtype (15). However,
the few Sox2lox/lox tumors showed reduced ASCL1 staining and increased NEUROD1/MYC
immunoreactivity (Fig. 5E). ASCL1, NEUROD1, and MYC staining showed nuclear localization
consistent with SCLC cells and not infiltrating cells (Supplemental Fig. S9). Blinded scoring of
the tumors as either ASCL1+ NEUROD1+, or MYC+ showed a significant increase in the number
of NEUROD1+/MYC+ tumors from the Sox2lox/lox mice (Fig. 5F, Supplemental Table S2).
Therefore, it appears that SOX2 favors the formation of an SCLC-A subtype.

Discussion
There have been a few indications that SOX2 may be a key factor in SCLC, however its role
in SCLC has so far been obscure. Rudin and colleagues showed that SOX2 is amplified in ~27%
of SCLC patients and cell lines, and that knockdown of SOX2 can impair growth of SCLC cell
lines (7). We have previously shown that RB1-loss, one of the two driver mutations required for
SCLC initiation, can result in SOX2 upregulation (23). SOX2 has been observed to be
misregulated in various cancers of the epithelium (66). As SCLC is a cancer that rises from the
lung epithelium, predominantly from pulmonary neuroendocrine cells which themselves express
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SOX2 during development, it seemed reasonable that SOX2 may indeed be a driver of SCLC (29,
67). However, the role for SOX2 in SCLC initiation and its mechanism in SCLC was unclear.
To that end, we generated a genetically engineered mouse model of SCLC based on the
RPR2 [Rb1lox/lox; p53lox/lox; Rbl2(p130)lox/lox] line, where we introduced a conditional Sox2lox/lox
allele (named the RPR2S line). We observed that deletion of Sox2 in these mice greatly hampers
the formation of SCLC tumors. The requirement of SOX2 in SCLC formation was not
completely penetrant, however, as there were a handful of small tumors that developed in the
absence of Sox2. These tumors had properties similar to the SCLC-N subtype as they showed
low levels of ASCL1 and high NEUROD1 and MYC. Therefore, SOX2 may be required
primarily for SCLC-A type tumors, which are the primary subtype of the RPR2 line, and that any
escapees were able to activate Neurod1 subtype networks to compensate and/or bypass the Ascl1
state.
To assess the function of SOX2, we assessed its genomic localization and observed that
SOX2 primarily binds to genes involved in neurogenesis, where neural gene signatures are
commonly found in SCLC (10, 11). Intriguingly, the genes bound by SOX2 did not strictly
overlap with SOX2 binding profiles in either pluripotent cells (ES and iPS cells) or NSCs. Rather
the SOX2 binding profile was most similar to glioblastoma multiforme, indicating that SOX2
may share a more common function amongst cancer than its well-studied functions in
development. This is perhaps unexpected as SOX2 has been described as a pioneer factor that is
able to bind its target DNA sequences regardless of any regional heterochromatin, and therefore
should be able to regulate target sequences in a wide assortment of donor cells (68). Rather we
observe that the cellular context does impart some level of regulation on the broader SOX2
network. This is particularly relevant considering that SCLC can arise from a few different cell
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types on the lung epithelium and can influence the resulting SCLC subtype (18, 29, 69). It is
possible that the few NEUROD1+/MYC+ lesions observed in the Sox2lox/lox mice are a result of
tumors initiating from a non-neuroendocrine lineage. Finally, what cell-type specific factors may
be constraining SOX2 function will be of particular importance towards understanding SOX2
regulation in SCLC, and potentially provide novel avenues for therapeutic targeting SCLC, and
perhaps other SOX2-driven cancers.
We observed two regulator networks that correlate with SOX2 expression in SCLC. The first
is ASCL1 that is required for SCLC formation in the RPR2 mouse model, and indeed is localized
at SOX2 indicating a direct role in SOX2 regulation (11). Consistent with ASCL1 lying upstream
of SOX2 in established SCLC cell lines, we observe that neither overexpression nor knockdown
of SOX2 alters ASCL1 expression. This prompts the question of how ASCL1 can lie upstream of
SOX2 if SOX2 upregulation is a direct consequence of RB1-loss, one of the two SCLC driver
mutations. It could be that RB1-loss promotes the derepression of SOX2, but ASCL1 activity is
required for full SOX2 transactivation and subsequent tumor development. Intriguingly, ASCL1
and SOX2 have been found at similar enhancer regions (70), therefore the regulation of these
two factors may not be strictly linear. Further investigation into the genetic networks at play in
early SCLC tumors will be required to address these questions.
With the potential link between SOX2 activity and ASCL1, we also investigated the other
neuroendocrine SCLC subtype specific factor, NEUROD1. SOX2 has been found to regulate
Neurod1 in neural progenitor cells, where it functions to maintain an epigenetically permissive
state at the Neurod1 promoter (71). Conversely, in neural stem cells of the adult hippocampus, it
was observed that SOX2 binds to the Neurod1 promoter and silences Neurod1 expression (72).
In SCLC, we observe that SOX2 overexpression leads to NEUROD1 silencing, while basal
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levels of SOX2 appear to be associated with activation or attenuation of the levels of activated
NEUROD1. This regulation appears direct as we observe SOX2 bound at the NEUROD1
promoter by ChIP, although binding at NEUROD1 was unclear in the CUT&RUN data. It is
possible that these two techniques may recognize different SOX2 protein complexes due to their
differing methods to assess DNA localization. As MYC is a target of NEUROD1 (11), SOX2 loss
could then promote a maintenance of the SCLC-N subtype network.
We also uncovered a role of SOX2 in the regulation of MYC and MYCL in SCLC. We
observe that endogenous levels of SOX2 appear associated with activation as SOX2 was found at
MYCL in SCLC-A subtype cell lines while it was bound at MYC in SCLC-N cell lines. Yet, in
contrast we observe that overexpression of SOX2 enhanced repression of MYC and MYCL in
SCLC-A and SCLC-N, respectively. As was shown for SOX2 in embryonic stem cells (61), we
also observe that SOX2 can be associated with both gene activation and gene silencing. The
alternating functions of SOX2 of both gene activation or repression most likely reflect differing
SOX2 protein complexes that are assembled in a context-specific manner, with tight
stoichiometric regulation of the endogenous activating complex so that overexpressed SOX2
favors the formation of a more promiscuous repressive complex. Further investigation into the
SOX2 protein interactome in SCLC and specifically in different SCLC subtypes will be required
to delineate the mechanistic function of SOX2 on different gene targets. SOX2, while typically
oncogenic in the lung (73, 74), can indeed act as a tumor suppressor when overexpressed in
multiple cancer types (75) indicating cell-type specific roles. Consequently, SOX2 may possess
differing functions, either favoring transcriptional activation or silencing in different cells within
a single SCLC tumor, or tumors that arise from alternative cells of origin as SCLC is indeed a
heterogeneous tumor comprised of multiple cell types responsible for tumor propagation and
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treatment resistance (19, 76-79). Further investigation into the mechanism of SOX2 activity in
these different cell types may shed additional light on the development of SCLC heterogeneity
and treatment resistance.
Together we have illustrated that SOX2 is strongly favorable to SCLC formation in the RPR2
SCLC mouse model. SOX2 serves to regulate NEUROD1 expression and is associated with the
switch from MYCL to MYC expression, although further investigation into its regulatory
mechanisms of this switch are required. ASCL1 is the predominant network controlling SCLC
activity in the early tumor; however, during tumor progression there is a switch to the
NEUROD1 state, driven in part by MYC and is linked with poorer patient outcomes (18, 79).
Our data indicates that SOX2 is associated with this process by the concurrent regulation of
NEUROD1, MYC, and MYCL. Understanding the genetic networks that underlie this switch
during SCLC tumor progression will add to the explanation of such processes as treatment
resistance, and ultimately lead to improved therapies to treat this devastating disease.
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Figure Legends
Figure 1 Sox2 is required for SCLC formation. A, Genetically engineered mouse model for the
study of Sox2 in SCLC. B, Representative H&E stained lung sections from Rb1lox/lox; p53lox/lox;
p130lox/lox; Sox2+/+ (left), Rb1lox/lox; p53lox/lox; p130lox/lox; Sox2+/lox (middle), and Rb1lox/lox;
p53lox/lox; p130lox/lox; Sox2lox/lox (right) mice, 6 months after Cre recombination. C, Number of
tumors as indicated by H&E staining 3 months after Cre recombination. D, Number of tumors as
indicated by H&E staining 6 months after Cre delivery. Numbers of mice used in C-D can be
found in Supplemental Table S1. E, Kaplan-Meier survival curve of SOX2 WT mice (Sox2+/lox)
compared to Sox2lox/lox mice. Violin plots show median (white dot), interquartile range (box) and
the continuous distribution of the data; significance for all panels determined by a two-tailed ttest where * = P<0.05, ** = P<0.01, *** = P<0.01.

Figure 2 RB represses SOX2 and is required for SCLC. A, Using 3 hairpins designed to murine
Sox2, (shSox2-1,2,&4) and one designed to human SOX2 (shSOX2-5) we tested the effect on
cellular proliferation by an Alamar Blue assay in KP1, KP3, H29, and H82 cell lines. B, Alamar
Blue assays of H29 and H1836 cells after transfection with RB1�CDK. C, Expression of Rb1
and Sox2 measured by qPCR after transduction of Adeno-Rb1 virus in KP1 and KP3 cells. D,
ChIP of HA-RB�CDK or mock transfected cells (H29 and H1836). Regions tested for ChIP
enrichment by qPCR are the SOX2 proximal promoter (PP), the SRR1 and SRR2 enhancers of
SOX2, MCM3 promoter as a positive control and ACTB promoter as a negative control. E,
Alamar Blue assay on day 4 to determine the proliferation of H29, H82, H1836, and H209 cells
after transfection with RB1�CDK, and or SOX2-t2a-GFP. Proliferation is plotted as the fold
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change compared to a mock-transfected control. Individual values are notated by grey circles.
Bar graphs show mean and SEM, significance for all panels determined by a two-tailed t-test
where * = P<0.05, ** = P<0.01, *** = P<0.01.

Figure 3 SOX2 regulates key SCLC pathways. A, SOX2 CUT&RUN heatmap from H1836 and
H29 cell lines. Each row represents the normalized read counts at all peaks identified for SOX2
binding. B, De novo motif identification discovers an HMG domain as the most prominent motif
in the SOX2 peaks. C, Top ten GO terms enriched at the genes associated with the SOX2 peaks.
D, PCA plot of other human SOX2 genome binding profiles. Studies include samples from
induced pluripotent stem (iPS) cells, embryonic stem (ES) cells, neural stem cells (NSCs) and
iPS-derived NSCs, and glioblastoma (GBM). Datasets include GSE69479, GSE81900,
GSE49405, GSE23839 (57-60). E, Density plot of the log(fpkm) values of all genes associated
with a SOX2 peak. F, Number of genes in (E) that are predicted to be part of the low- or highexpression group after Gaussian mixed model clustering (Supplemental Fig. S4). G & H,
WGCNA identified two networks that include ASCL1 and MYC. Color scale reflects the relative
expression of each gene in the network from the expression profiles available in the CCLE.

Figure 4 SOX2 partially regulates NEUROD1 A, Heatmap of the log transformed fpkm values
from SCLC cell lines from CCLE. Cell lines are clustered independently from SOX2 expression.
B, Transfection of H1836 and H209 (SCLC-A) and H29 and H82 (SCLC-N) with SOX-t2a-GFP.
qPCR of ASCL1 and NEUROD1 are shown. C, qPCR of ASCL1 and NEUROD1 are shown upon
Cas9-mediated knockdown of SOX2. D, Western blots for NEUROD1, SOX2, and TUBULIN
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after SOX2 overexpression or a mock transfected as a control. E, Quantitation of NEUROD1
protein levels as assessed by western blotting as in (E), n=3. F, ChIP of SOX2 or an IgG control
assessed by qPCR at SOX2, NEUROD1, ASCL1, MYC, and ACTB as a negative control. Bar
graphs show mean and SEM, significance for all panels determined by a two-tailed t-test where *
= P<0.05, ** = P<0.01, *** = P<0.01.

Figure 5 SOX2 is a regulator of MYC and MYCL in SCLC. A, Gene track showing SOX2
CUT&RUN at the MYC and MYCL loci in H1836 and H29 cells. Blue/green track represents the
normalized read maps across the loci, the black bars under the track represent regions where
significant peaks were called. B, qPCR of MYC and MYCL in H1836 and H209 (SCLC-A) and
H29 and H82 (SCLC-N) plotted as a log2 ratio of SOX2 overexpressed cells to the mock control.
Values greater than one indicate higher expression upon SOX2 overexpression. Significance
determined by a two-tailed t-test C, Quantitation of MYC protein levels as assessed by western
blotting as in (D), n=3. D, Western blot of MYC, SOX2, and TUBULIN after SOX2
overexpression or mock transfected cells as a control. E, Immunohistochemistry of ASCL1,
NEUROD1, and MYC in murine SCLC tumors. Representative tumors shown. Scale bar = 100
�m. F, Quantification of tumors scored as ASCL1+, NEUROD1+, or MYC+ expressing in (E).
Number of tumors and their staining classifications are notated in Supplemental Table S2.
Significance assessed by ANOVA. Bar graphs show mean and SEM, significance identified
where * = P<0.05, ** = P<0.01, *** = P<0.01.
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ABSTRACT
The processes that underlie neuronal conversion ultimately involve a reorganization of
transcriptional networks to establish a neuronal cell fate. As such, transcriptional profiling is a
key component towards understanding this process. In this chapter, we will discuss methods of
elucidating transcriptional networks during neuronal reprogramming, and considerations that
should be incorporated in experimental design.

KEY WORDS Neuronal conversion, Induced neurons, Transcriptional profiling, RNA-seq
1 INTRODUCTION
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Cellular reprogramming is a powerful process that harnesses the potential of the genome
to alter a cell’s identity. Typically, the direct conversion process involves the transfer of
cDNAs, mRNAs, or proteins that harbor master regulator activities, or small molecules that
influence master regulator function to a differentiated cell type to drive the conversion of that
cell to one of a different lineage, without going through a pluripotent intermediate. This
approach utilizes the existing genetic material in a cell to lead to transcriptomic changes that
drive cell fate conversion. One of the first and best-studied systems for understanding direct
conversion is the formation of induced neuronal (iN) cells. Reported in 2010 from the lab of
Marius Wernig, the first account of fully functional iN cells being induced from mouse
fibroblasts used a three-factor reprogramming cocktail [1]. Since then, a number of groups
have recapitulated this process, with slightly different combinations of factors and culture
conditions using both human and mouse differentiated cells as source material [2-6,1,7-9].
Generally, reprogramming of iN cells is defined and characterized by a number of
morphological, molecular, and functional parameters [7], however given that the factors
supplied to drive reprogramming are often transcriptional regulators such as Ascl1,
transcriptional profiling should serve as a powerful tool for the understanding of
transcriptional states of these cells [10,11,5,6]. Transcriptomic profiling of reprogrammed
cells allows for the understanding of the complex transcriptomic changes that occur during
cell fate switching, aids in understanding lineage hierarchies, and identifies transcriptional
targets of the reprogramming factors.
A powerful player in the field of transcriptomic profiling, RNA sequencing served for
many years as the foremost technique in understanding gene expression at a tissue level. In
this method of bulk transcriptomics, the expression of all RNAs in the cellular population is
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sequenced and used to generate an expression profile of the sample, allowing for the
evaluation of transcriptional networks that are activated or repressed during the
reprogramming process [12]. Bulk RNA sequencing at various timepoints throughout the
reprogramming process has been used to uncover lineage pathways that emerge as these cells
are reprogrammed [13]. The transcriptomic data gained from bulk RNA sequencing can be
used to determine in an unbiased manner the fate of reprogrammed cells and illuminate the
intermediate states that were traversed during reprogramming [10,14,15].
While bulk RNA sequencing is an important tool for understanding the transcriptome of
iN cells, it does not account for the heterogeneity of cellular populations that occurs in tissues
or during the reprogramming process. Bulk approaches average the contribution of the
transcriptome of all the cells, which can lead to the masking of rare populations within the
sample. An emergent powerhouse in transcriptomic analysis, single cell RNA sequencing
(scRNA-seq) instead evaluates the transcriptome of each individual cell in a population, and
using complex bioinformatics tools, can stratify individual populations of cells within a
sample to determine a more complete picture of the state of these cells. Using scRNA-seq,
we have the ability to evaluate differential gene expression within a sample, draw lineage
maps, and identify rare or novel populations [16-18]. scRNA-seq has been used in the field
of iN differentiation, and has helped to identify the transcriptional networks that “prime” a
cell for differentiation, and create a comprehensive profile of transcriptional reprogramming
states [19]. Using scRNA-seq to uncover the lineage path and single-cell transcriptomes
regulated at various timepoints throughout reprogramming has led to the comprehensive
characterization of clonal populations and heterogeneity present during iN reprogramming
[5]. While scRNA-sequencing is a powerful tool for transcriptional profiling, due to its high
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sensitivity, special considerations must be taken to ensure analysis faithfully recapitulates the
biological phenotypes [16,18,20].
This protocol will describe the general methods and considerations that should be
considered in the transcriptomic analysis of iN transcriptome analysis. Due to the wide
variety of methods to prepare samples for transcriptomic analysis, and since many of these
involve the use of proprietary kits with established protocols, we will instead focus on the
sample design considerations and downstream data analysis in regards to understanding the
changes in the transcriptome during neuronal reprogramming.

2 MATERIALS
1. Basic RNA-extraction methods such as Trizol to isolate RNA for bulk RNA-seq or
scRNA-seq library preparation platforms such as a 10X Chromium Controller (10X
Genomics, Pleasanton, CA, USA) or a Fluidigm C1 system (Fluidigm, South San
Francisco, CA, USA).
2. Large computational resources that run on a UNIX environment for most command-line
software. An installation of R is required for many computational tools and can be run in
a Unix, Windows, or iOS environment [21].
3 METHODS
3.1 Bulk RNA-seq of reprogrammed cells
Study designs in cell reprogramming typically involve time course sampling to monitor changes
in expression profile as cell differentiation progresses. A minimum of three replicate samples
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from each time point is required for statistically reasonable results. For studies involving bulk
RNAseq, differential gene expression analysis is typically followed by downstream pathway
enrichment analysis.
Bioinformatics analysis pipeline is depicted in Figure 1 and the details of the steps involved are
provided below.
a. Checking the quality of sequencing. Raw reads from sequencer are typically in the form
of fastq format and come in general with adapter sequences clipped. Nevertheless, it is
good practice to first do quality assessment of the reads and check for presence of adapter
contamination. The most commonly used tool for quality is FASTQC [22] and for
trimming Trimmomatic [23].
b. Alignment to reference genome. There are several widely used packages for alignment
of reads to the reference genome, including Hisat2 [24], STAR [25].
c. Read counting. Reads mapping to genomic regions (genes) are counted using several
commonly used packages like featurecounts in Rsubread package [26] and HTseq-count
[27]. STAR aligner has “quantoMode” option in the mapping stage that counts reads.
d. Differential gene expression. A full statistical model of expression in relation to
condition and time points and their interaction (Expression ~ Condition + Time +
Time*Condition) and a reduced model (Expression ~ Condition + Time) are run in
DESeq2 [28]. Then a likelihood ratio test between the full and reduced models evaluates
changes in expression between conditions at any time points beyond the first. This can be
followed by clustering analysis to identify groups of genes that share a similar expression
profile in time. Other packages that are frequently used and have capabilities for the
above two mentioned tests are EdgeR [29] and limma [30]. An alternative approach is to
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model expression as a continuous function of time to find genes that show significant
difference in their pattern or to cluster genes based on their similarity of expression
trajectory in time. The R packages maSigPro [31] and ImpulseDE2 [32] perform well for
identifying significant changes in time and between conditions. The python package
DPGP (Dirichlet process Gaussian process mixture model) can be used to identify groups
of genes with similar temporal trajectory [33].
e. Gene set enrichment. Pathway analysis in RNAseq data is primarily done using the
hypergeomeric test, evaluating overrepresentation of pathways given the differentially
expressed genes. However, there is length bias in the probability of being differentially
expressed (DE), which is inherent in RNAseq data. This combined with the difference in
length distribution of genes within pathways leads to bias in enrichment analysis. The
result is that pathways that are disproportionately composed of large genes will more
likely be declared enriched in all conditions making the analysis lack specificity to the
condition being investigated. By controlling for gene length the package GOseq [34]
yields enrichment results that are more relevant to the study at hand. Commonly used and
publicly available gene sets include the Gene Ontology Consortium [35,36], The Kyoto
Encyclopedia of Genes and Genomes (KEGG) [37], and a collection of gene sets at the
Broad Institute [38].

3.2 Single cell transcriptomic analysis of neuronal conversion
Singe cell RNAseq data suffers from high technical variability that arises during sample
processing. This can be minimized by ensuring that multiple biological replicates are mixed in
each batch [39]. Cells within batches are later assigned to samples based on unique genotypes
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for example using Demuxlet [40]. scRNAseq analysis pipeline is different from the bulk
RNAseq in the preprocessing stages and in the statistical analysis of the expression data.
scRNAseq data is typically multiplexed with unique identifiers provided for each cell and
sometimes for individual transcripts. Preprocessing steps are thus required to assign reads to
their respective unique cells. Subsequent steps are similar to bulk RNAseq analysis. Statistical
analysis of scRNA data initially is a classification problem with the objective being to find
unique groupings of the cells based on their similar expressions. Once groupings are identified,
differential expression tests between groups are used to find unique markers for each unique cell
group.
Bioinformatics analysis pipeline is depicted in Figure 2 and the details of the steps involved are
provided below.
a. Demultiplexing of reads. Many sequencers supply individual fastq files for each
sample/cell. In some cases, one fastq file containing all cell barcodes and sample
mapping is provided. In this this case, demultiplexing tools like Sabre [41], UmiTools
[42], and zUmi [43] are used to allocate reads to their respective samples, strip the
barcode and UMI from the reads, and create individual fastq files for each cell.
b. Alignment to reference genome. Unlike bulk RNAseq, scRNAseq data set comprises
thousands of cells. As result, the mapping step requires fast algorithms to get results in
reasonable time. STAR and Kallisto are the two fast aligners that are routinely used in
scRNAseq data analysis [25,44].
c. Quality control of cells. Indicators of poor quality cells include prevalence of large
number of mitochondrial genes and very low or very large numbers of genes [45].
Prevalence of mitochondrial genes is an indicator that the cell was not viable. Very low
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number of detected genes implies that the starting material is an empty droplet. While
large number of genes implies multiple cells in a droplet. To retain good quality cells
based on the above criteria, it is best practice to explore each dataset and find outlier cells
to remove from the dataset. The R package Seurat [46] package has procedures to explore
and visualize the distribution of the number of genes and percentage mitochondrial genes.
These can be used to set cutoff points relevant to the data at hand. Good quality cells
also tend to have higher mapping rate, lower number of duplicates and lower ERCC
spike-in to exonic read counts ratio [45]. Since these metrics are likely to differ from
study to study, a reasonable approach is to explore their distribution (e.g distribution of
number of unique mappers) across all cells and remove cells that are outliers [e.g. see
47].
d. Normalization. Choice of normalization along with the library preparation method has
the biggest effect on the downstream analysis of differential expression in scRNAseq data
[48]. Normalization methods developed for bulk RNAseq data are usually not appropriate
for scRNAseq data [49]. Methods developed for scRNAseq include BASiCS [50], GRM
[51], SCnorm [52], and Scran [53]. Using simulated data, Vallejos et al (2017) and Vieth
et al (2019) evaluated bulk-based and scRNA-specific methods and found that Scran and
SCnorm provided a better normalization with stable number of highly variable genes for
clustering. The widely used scRNA analysis package Seurat has built-in lognormalization methods. For robust results, data is first normalized using methods specific
to scRNA such as Scran or SCnorm. The normalized data can then be fed in to popular
scRNA tools such as Seurat.
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e. Clustering of cells. Unsupervised clustering methods and dimension reduction
techniques are combined to partition cells in to distinct groups based on distance. Among
the dimension reduction techniques typically used are Principal Components Analysis
(PCA), tSNE, and UMAP. These also are critical in data visualizations on lower number
of dimensions for assessing cell clusters.
f. Marker gene identification and labeling. Once the unique cells are identified, tests are
conducted to find marker genes that are differentially expressed in each group in contrast
to the others. The AllMarkers function in Seurat (R package) conducts DE test and has
options for different types of tests including Negative binomial as in DEseq2. To label
the cell types, marker genes from each cell type are compared with markers from known
cells. Where available, correlation analysis between the identified cell types and gene
expression data from known cell types or from bulk RNAseq data from tissues enriched
with cells of interest can be used as a strong indicator of cell identity. One can also
conduct pathway enrichment analysis for each identified cell type to determine their
putative functions. Confidence on the identity of the cell types can be strengthened if
evidence from presence of markers, high correlation, and presence of cell specific
pathways is combined.
g. Ordering of cells based on expression trajectory. There is a large selection of methods
for ordering of cells based on the progression of their expression [54]. Choice of which
methods to use depends on the kind of trajectory one is looking for, i.e. linear, cyclic, or
tree. In their extensive evaluation of 29 different methods, Saelens et al (2019), found
that methods perform well in correctly detecting trajectories they were originally
designed for. Based on their results, the authors provide a practical guideline for choosing
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an appropriate tool. For example reCAT [55], outperforms other methods when the
underlying trajectory is a cycle. While Monocle DDRTree [56-58], Slingshot [59] and
TSCAN [60] perform well if the underlying trajectory is a more complex branching tree.
Slingshot and TSCAN perform well when the underlying trajectory is a bifurcation. For
discovering linear trajectories SCORPIOUS [61] performs better. Besides finding the
trajectory some of these tools provide functions to find genes that cause bifurication
(Slingshot) or show marked changes along the trajectory eg. Monocle DDrTree,
Slingshot, and TSCAN. A recently developed tool tradSeq [62], can be used downstream
of the above packages to detect differential expression of genes along a lineage or
between lineages. Using general additive models, TradeSeq fits gene expression as a
continuous function of psuedotime which affords flexibility in identifying marker genes
at different points.
h. Elucidating differentially regulated genetic networks. Pathways enrichment analysis
in scRNA is conducted similarly as in bulk RNA-seq data using the package GOseq [34].
Pathway enrichment analysis on marker genes of each unique cell type can help highlight
differences in function between cells. Similarly, pathways enriched in genes that cause
bifurcation events or genes that show significant changes along lineages can be
identified. In these cases, these biological processes are the putative causes of the
branching events or the differentiation of the cells.
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Figure 1 Analysis pipeline for bulk RNA-seq
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Figure 2 Analysis pipeline for scRNA-seq
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